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Abstract
Multidrug-resistant Mycobacterium tuberculosis (MDR-TB) is a leading cause of
morbidity and mortality in the Philippines. The purpose of this study was to gain
knowledge about the relationship between potential risk factors and MDR-TB. Risk
factors (the independent variables) for MDR-TB (the dependent variable) include
previous TB treatment, infection with HIV, exposure to patients with drug-susceptible
TB/MDR-TB, delays in diagnosis and treatment, employment status, smoking,
imprisonment, alcohol abuse, and poor compliance with TB treatment regimens. The
study was based on the epidemiological approach to causal inference work. A casecontrol study design was used wherein a quantitative method was applied in data analysis
to assess the strength of the pre-identified possible risk factor(s) association to MDR-TB
infection. Data were collected using survey questionnaires that were administered to
patients (N = 172) from health centers in Leyte, San Mateo Rizal, and San Lazaro.
Hypotheses were tested using chi-square analysis, Fisher’s exact test, and an odd ratio.
Drug-susceptible TB respondents who smoked on a daily basis were 3 times more likely
(95% CI 1.021-13.341, OR 3.69) to develop an MDR-TB infection than were other
respondents. Respondents who did not comply with the anti-TB treatment regimen were
9 times more likely (95% CI 2.104-43.059, OR 9.519) to develop an MDR-TB infection
than other respondents. Health care providers may be able to use study findings to
develop programs to help drug-susceptible TB patients stop smoking and better comply
with treatment regimens designed to prevent MDR-TB infection, resulting, potentially, in
improved public health outcomes for patients.
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Chapter 1: Introduction to the Study
Introduction
Data from the World Health Organization (WHO, 2013a) show that, in 2012, 8.6
million people globally were infected with tuberculosis (TB), and 1.3 million died of the
disease. Low- and middle-income countries accounted for 95% of TB deaths (WHO,
2013a ). More people are dying of the disease with the emergence and proliferation of
multidrug resistant–tuberculosis bacteria (MDR-TB; WHO, 2013a).
In 1994, epidemiologists began to monitor drug-resistant TB through WHO’s
Global Project on Anti-Tuberculosis Drug Resistance Surveillance (Zignol et.al, 2012).
The project goal is to assess epidemiological trends of the disease . Data collected and
analyzed from 127 countries, representing 66% of WHO’s 193 member states, show that
0-28.9% of TB cases in 2007-2010 were multidrug resistant (Zignol et.al, 2012).
Enrollment for MDR-TB treatment increased from 2009 to 2012 and is projected to
further increase by 2015 (see Figure 1).
In response to the aforementioned findings, public health experts from WHO
developed a six-point strategy as part of the Global Plan to Stop TB program (WHO,
2014e). The program’s primary goal is to reduce the global burden of the TB disease by
2015 (WHO, 2014e). The continued evolution of the TB causing organism strain to be
antibiotic-resistant could potentially hamper the realization of the Global Plan to Stop TB
program.
Several factors have been observed towards a successful treatment of MDR-TB
infection. Among which are manipulation of the medicine to suit the pediatric patient,
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some patients are experiencing adverse effect of the medicine since its more toxic, 2 years
or longer treatment period, daily injections for 6 months and much more expensive (TB
Alliance, 2013). The longer treatment period can cause side effects which result in poor
adherence to the treatment regimen (TB Alliance, 2013). As a consequence, the disease
becomes more difficult and costly to treat each time a patient does not complete his or her
course of drugs (TB Alliance, 2013).

Figure 1. Drug susceptibility testing coverage among new cases and enrollment in MDRTB treatment compared with the targets in the Global Plan to Stop TB, 2011–2015.
Lines indicate the planned targets; blue squares, the situation in 2009–2012, and orange
circles, the projected enrollments in 2013–2015. Data on projected enrollments in 2015
were incomplete. Adapted from Global Tuberculosis Report 2013, page 52. Copyright
2013by the World Health Organization.
Epidemiologists are concerned about the rise in MDR-TB cases globally and poor
treatment outcomes. The number of cases reported has tripled between 2007-2010 (WHO,
2013a). In the 2010 profile, only 48% or so of MDR-TB patients in the cohort had
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successfully completed treatment (WHO, 2013a). Twenty-eight percent of cases were
reported as lost to follow-up or had no outcome information (WHO, 2013a; see Figure 2).

Figure 2. Global treatment outcomes for patients diagnosed with MDR-TB by WHO,
2007–2010 cohorts.The total numbers of cases with outcome data are shown beside each
bar. Adapted from Global Tuberculosis Report 2013, page 57. Copyright 2013 by the
World Health Organization.
Understanding the risk factors related to the onset of a disease is very critical in
epidemic prevention. The information obtained in the primary prevention stage is of
greatest value before the biological onset of illness. The persistent increase in the
prevalence rate of TB, specifically MDR-TB continues to concern among public health
practitioners (WHO, 2013a).
Background
The high global death rate of TB is due to the presence of the pathogenic causative
agent Mycobacterium tuberculosis (Mtb), according to researchers (National Institute of
Allergy and Infectious Diseases [NIAID], 2010). This organism is aerobic and rod-shaped
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and is present in people with active TB (NIAID, 2010). It can remain dormant for years
without causing any TB disease symptoms (latent TB) but may eventually become active
TB (NIAID, 2010).
Mtb is a very resilient phototrophic organism. The bacterium can adapt to changes
such as nutrient deprivation, hypoxia, and various exogenous stress conditions throughout
the course of infection (Cook et al., 2009). The ability of the organism to adapt to
environmental changes is due to the presence of complex regulatory networks and signals
that result in temporal gene expression coupled with metabolic and energetic changes
(Cook et al., 2009). The front line drugs against Mtb infection are isoniazid and
rifampicin. In cases of MDR-TB infection, however, the bacterium is resistant to isoniazid
or rifampicin (XDR-TB; WHO, 2014b). When the Mtb bacterium strain is resistant to
ofloxacin or moxifloxacin or other second-line drugs, the disease is classified as
extensively drug-resistant tuberculosis (XDR-TB; WHO, 2014b).
Historical Perspective of TB
The rich history of tuberculosis dates back to the Stone Age. Around 460 BC,
Hippocrates called the disease “phthisis.” In modern times, the disease began to be called
TB (Mackenzie, 2012). It reached the Americas well before Columbus (Mackenzie, 2012).
After 1600, TB became pandemic and rampaged throughout Europe. TB caused a quarter
of all deaths by the 1800s (Mackenzie, 2012). DNA analysis of ancient human remains
obtained from southern Germany (1400–1800 AD), Hungary (600–1700 AD), and Egypt
(3500–500 BC) revealed high frequencies of TB in all time periods (Zink, 2007).
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Observers became optimistic about eradicating TB after Robert Koch discovered
and stained the causal organism in 1882 (NIAID, 2010). This was followed 60 years later
by the discovery of antibiotics such as streptomycin (1943), isoniazid (1951),
pyrazinamide and cycloserine (1952), ethionamide(1956), rifampin (1957), and
ethambutol (1962; Keshavjee & Farmer, 2012). The influx of anti-TB drugs in the market
has allowed the Mtb organism to adapt in the form of a mutation conferring resistance to it
(Keshavjee & Farmer, 2012). Thus, epidemiologists monitored anti-TB drug resistance in
Britain from 1955-1956 and in the United States from 1965-1968 (Keshavjee & Farmer,
2012). In a 2000-2004 study on Mtb isolates, researchers at Supranational Reference
Laboratories concluded that the presence of XDR-TB throughout different world regions
resulted from improper treatment of MDR-TB infection (Shah et al., 2007). The surge in
MDR-TB infection has been attributed to the increasing resistance of the Mtb organism to
more than one anti-TB drug (NIAID, 2010).
Risk Factors for MDR-TB Infection
Risk factors for the development of MDR-TB infection vary considerably
depending on the population studied, the reason for the research investigation, and the
methodology that is applied. In a retrospective study conducted in South West Nigeria
among pulmonary TB patients with MDR-TB, of the 88 respondents, 55 were resistant to
at least one antibiotic against Mtb (Daniela & Osmanb, 2011). Resistance was showed to
be associated with previous history of anti-TB treatment (Daniela & Osmanb, 2011). Data
revealed that age (OR = 0.86 [95% CI 0.35-2.13]; p = 0.72) and gender (OR = 1.24 [95%
CI 0.49-3.14]; p = 0.62) were not significantly associated with drug resistance (Daniela &
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Osmanb, 2011). The authors recommended conducting a national TB drug resistance
survey specific to South West, Nigeria. The primary aim of the survey was to determine
the actual burden and risk factors associated with drug resistance to TB (Daniela &
Osmanb, 2011).
Previous history of anti-TB treatment was identified as a risk factor for MDR-TB
infection in a study conducted in the Republic of Georgia. The study was performed from
July 2005 to May 2006. Previous TB treatment and female gender were identified as risk
factors of MDR-TB (Lomtadze et al., 2009). The identification of the female gender as an
MDR-TB risk factor contrasted Daniela and Osmanb’s (2011) findings wherein gender
was found to be associated to MDR-TB infection.
In Belarus, a nationwide survey to assess the prevalence of MDR-TB and to
investigate associated risk factors was conducted from 2010 to 2011. Possible risk factors
associated with the development of MDR-TB in the study were age, country of birth, TB
treatment history, the level of education, living conditions, household size, employment
status, history of imprisonment, alcohol consumption, history of smoking and HIV status
(Skrahina et al., 2013). Previous TB treatment was found to be the strongest risk factor
followed by HIV infection, age, history of imprisonment, disability sufficient to prevent
work, alcohol abuse and smoking (Skrahina et al., 2013).
Residents living in the old urban areas in Vietnam and is infected with the Beijing
genotype of Mtb bacteria and is infected with HIV is an associated risk factors for MDRTB infection in a study performed in Hanoi, Vietnam (Hang et.al. 2013). The researchers
recommended that careful monitoring be undertaken in areas with a high proportion of the
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Beijing strain of Mtb and HIV infection to avoid transmission of MDR-TB (Hang et.al.
2013). However, no clear association between time and geographic location of MDR-TB
and HIV infection was observed in a metaanalysis study performed by Suchindran,
Brouwer, and Van Rie (2009). The researchers aimed to determine if HIV infection is a
risk factor for the MDR-TB infection (Suchindran, Brouwer, and Van Rie (2009). The
researchers were not able to demonstrate an overall association between MDR-TB and
HIV or acquired MDR-TB and HIV. These data suggest that HIV infection is associated
with primary MDR-TB infection. The researchers recommended that other studies be
conducted to better clarify the relationship between MDR-TB and HIV for all regions of
the world (Suchindran et. al., 2009).
Ricks et al. (2012) studied the possible risk factors for the development of MDRTB in Namibia using 117 confirmed cases of MDR-TB. The authors found that risk
factors associated with the MDR-TB infection were previous hospitalization (OR 1.9, 95%
CI 1.1–3.5) and contact with a household member with MDR-TB (OR 5.1, 95% CI 2.1–
12.5). These studies show that there is no clear understanding of the risk factors that can
be associated with MDR-TB infection for it may vary with the socio, cultural,
demographic and economic conditions prevailing in a country.
Problem Statement
In a study completed as part of the Tuberculosis Profile of the Philippines, 2003–
2011, Vianzon, Garfin, Lagos, and Belena (2013) found that 98.9% of the 379,390
diagnosed cases were pulmonary TB. Further, TB was found to be the sixth leading cause
of morbidity and mortality in the Philippines. The country has one of the highest numbers
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of MDR-TB cases and ranks as ninth among the 22 highest TB-burden countries in the
world (Vianzon, Garfin, Lagos, and Belena, 2013). The emergence of MDR-TB poses a
serious threat to TB control in developing countries like the Philippines. Besides being
difficult and expensive to treat, the disease requires a longer period of treatment. The
Tuberculosis financing profile of the Philippines showed that for 2016 the Philippine
Department of Health requires $104 million US dollars to operate the TB prevention and
control program. However, only 21% of the required program cost will be provided by the
government, 41% international grants, while 38% was unfunded (WHO, 2014a). Further,
data showed that in the Philippines, 4% of all new TB cases have MDR-TB, and 4.6% of
all drug-resistant TB cases have XDR-TB (WHO, 2014a).
I performed a query in the WHO interactive database on the treatment outcomes of
MDR-TB cases in the Philippines. Figure 3 shows that only 49% of the reported MDR-TB
cases in 2013 were successfully treated. The figure also shows that 12% died, 1% failed
treatment, 29% were lost to follow-up, and 8% were not evaluated (WHO, 2014c).

Figure 3. Indicators of diagnosis, notification, and treatment of multidrug-resistant TB,
by region or country and year Adapted from Diagnosis, Notification and Treatment of
Rifampicin Resistant TB (MDR-RR TB). From Interactive tuberculosis data visualizations
World Health Organization.
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The Philippines Department of Health Tuberculosis Control program approved the
conduct of the study for there is no study at the present that identify national and
geographically relevant risk factors for MDR-TB infection in the Philippines. The
identification of risk factors is critical for TB disease prevention and control, especially in
the Philippines where public health resources are limited. A person who is identified as
having an increased risk for diseases can participate in laboratory testing and receive
treatment prioritization. Early treatment may minimize the detrimental biological,
psychological and social effects TB disease.
Nature of the Study
The study followed the quantitative methodology and used a case-control design.
The control subjects were selected among patients with drug-susceptible Tuberculosis, and
the cases were patients with clinically confirmed MDR-TB. The study subjects were
patients who have been clinically confirmed to be MDR-TB positive. MDR-TB infection
is the dependent variable of the study wherein the condition already occurred to patients.
The study l used a semi-structured questionnaire to collect relevant information from
enrolled participants.
The quantitative analysis aimed to assess if there is a statistically significant
relationship between each identified risk factor and the MDR-TB infection. If no
statistically significant causal relationship is established, the specific risk factors will not
be considered as direct risk factors (Porta, 2014).
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Research Questions and Hypotheses
I sought to answer the following research question: Is there an association between
MDR-TB infection and the following possible risk factors: previous TB treatment,
infection with human immunodeficiency virus, exposure to a drug-susceptible TB/MDRTB patient, delay in diagnosis and treatment, employment status, smoking, imprisonment,
alcohol abuse, and compliance with TB treatment regimen. I tested the following
hypotheses:
H01: MDR-TB infection is not associated with any of the following possible risk
factors as determined by the standardized questionnaire: (a) previous TB treatment; (b)
infection with human immunodeficiency virus; (c) exposure to drug-susceptible TB/MDRTB; (d) delayed in diagnosis and treatment; (e) employment status; (f) smoking; (g)
imprisonment; (h) alcohol abuse and (i) compliance with drug-susceptible TB treatment
regimen.
H11: MDR-TB infection is associated with one or more of the following possible
risk factors as determined by the standardized questionnaire: (a) previous TB treatment;
(b) infection with Human Immunodeficiency Virus; (c) exposure to drug-susceptible
TB/MDR-TB; (d) delayed in diagnosis and treatment; (e) employment status; (f) smoking;
(g) imprisonment; (h) alcohol abuse and (i) compliance with drug-susceptible TB
treatment regimen.
Purpose of the Study
In this study, I assessed the strength of association between identified risk factors
and the development of the MDR-TB infection in the Philippines. Specifically, I examined
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whether the following factors are causally associated with MDR-TB infection: (a)
previous TB treatment, (b) infection with HIV, (c) exposure to a drug-susceptible
TB/MDR-TB patient, (d) delay in diagnosis and treatment, (e) employment status, (f)
smoking, (g) imprisonment, (h) alcohol abuse, and (i) compliance with TB treatment
regimen. Findings may inform efforts by public health professionals and other
stakeholders in the community to develop effective proactive intervention programs to
enhance MDR-TB prevention in the Philippines.
Theoretical Foundation
This study is anchored in the epidemiological theory of John Snow. He pioneered
the epidemiological approach to causal inference work with an emphasis on the evaluation
of preventive, ameliorative, and curative interventions (Fine et al., 2013). The theory
provided an understanding of the agent, the environment and host as a framework for the
dynamics of disease transmission.
Snow’s epidemiological approach started during the outbreak of cholera epidemic
in London which occurred in 1831–1832 and in 1848–1849 where he used skilled
reasoning, graphs, and maps to demonstrate the impact of presumed Vibrio cholera
contaminated water coming from the Broad Street pump. The ideas from the
epidemiological study of Dr. Snow were published in his book On the Mode of
Communication of Cholera in 1855 which later was republished as a classic work in
epidemiology, resulting in lasting recognition of his work (Frerichs, 2009).
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Definitions
I have defined the following terms to clarify the terms and variables I used in my
investigation:
Acquired resistance: Patients diagnose with TB and taking the anti-tuberculosis
drug and subsequently acquire resistance (WHO, 2009).
Cured: Patients that completed the course of anti-tuberculosis treatment and
laboratory analysis from 5 consecutive sputum cultures demonstrated the absence of the
Mtb (WHO, 2009).
Efflux mechanism: The movement of the antibiotic compound out of the cell
(Machado et al., 2012).
Efflux pumps inhibitors: Compounds such as thioridazine, chlorpromazine, and
verapamil that prevents the movement of antibiotic out of the cell (Machado et al., 2012).
Failed treatment: Patient demonstrated viable Mtb from sputum culture despite the
12-month antituberculosis therapy (WHO, 2009).
Multidrug resistant tuberculosis: a condition wherein the strain of Mycobacterium
tuberculosis is resistant to at least isoniazid and rifampicin (Zignol et al., 2012).
New case: Patients who denied during direct questioning having had any prior antituberculosis treatment for up to one month (WHO, 2009).
Recurrence of TB after treatment: Reinfection of antibiotic resistant Mtb organism
after treatment from MDR-TB.
Possible risk factor(s): Variables in the study such as previous TB treatment,
infection with human immunodeficiency virus, exposure to drug susceptible TB/MDR-TB
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patient, delay in diagnosis and treatment, demographics (e.g., age and gender), social
factors (e.g., smoking, imprisonment, unemployment, and alcohol abuse), and recurrence
of TB after treatment.
Preferential social mixing: Individual that chooses to associate with others that
have similar HIV-status and lower average CD4 counts among HIV-seropositive
individuals (Sergeev, Colijn, Murray, & Cohen, 2012).
Previously treated: Patients upon direct questioning admit having been treated for
TB for 1 month or more (WHO, 2009).
Primary resistance: Patients who have been previously treated for TB but with
resistance to one or more anti-tuberculosis drug (WHO, 2009).
Treatment regimen: Use of MDR-TB - HRZES (H-Isoniazid 300mg, R-Rifampicin
450mg, Z-Pyrazinamide 1g, E-Ethambutol 800mg, S-Streptpmycin1g) for the first 2
months, then HRZE for the third month during the intensive phase (Department of Health
Government of the Philippines, 2003).
Treatment regimen survey: A type of survey that aims to measure first-line and/or
second-line drug resistance among a group of selected patients who cannot be considered
representative of a patient population (WHO, 2009).
Limitations and Assumptions of the Study
My interactions with study subjects are one of the limitations of the study. In
addition due to the archipelagic location of the country, study participants will be limited
in number and may potentially affect the generalizability of the study results. Study
participants were obtained from the different Department of Health - National
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Tuberculosis Control Program treatment centers/hospitals in the country such as San
Lazaro Hospital and various town health center in the province of Leyte and Rizal.
Specifically in the towns of San Mateo, Burauen, Dagami, Tanauan, Capoocan, Cariga
and Barugo. Medical records in the Philippines, especially in some clinics/hospitals
located outside the capital city, are paper based. Access and completeness of medical
records provided a limitation in the verification of patient data and consequently in the
enrollment of cases. Patients from clinics/hospitals where medical record data are not
complete were considered for enrollment in the study. This lead to potential selection
bias, where more participants from urban areas are enrolled in the study. Another
limitation of the study was that since data collection was through the use of the
questionnaires with regards to the respondents past events, recall bias was potentially
introduced which in most cases items in the questionnaire were left unanswered. The
researcher requested respondents to answer unanswered questions during the final review
of the questionnaire. However, in most cases, they refuse to provide an answer which was
respected by the researcher. The high rate of unanswered questions provided bias to the
study test results; thus study conclusion cannot be applied to the general population.
The assumption of the study is that the laboratory-confirmed study respondents with
MDR-TB are correct and reliable based on the input from the clinician, including the
assumption that the study respondents will provide information to the best of their ability.
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Significance of the Study
Identifying country specific relevant risk factors of MDR-TB infection that are
reflective of the socio, cultural, economic, and demographic conditions in the area may
help prevent the proliferation of the disease. The identification of risk factors can provide
guidance to health care professionals in the identification of high-risk patients, thus
increasing the effectiveness of MDR-TB prevention program in the Philippines. It is
hoped that the results of the study will provide public health officials an additional basis
for programmatic priority planning and policy decision making in the practice of public
health. Also, the study can perhaps aid public health practitioners to identify the risk
differences which can help prioritize resource allocation for the surveillance, control, and
prevention of MDR-TB. The data that were generated from this study may have a
potential impact on public health educators and help them educate the general public on
the modifiable risk factor(s) to prevent if not decrease MDR-TB infection. This study
hopes to fill in the gap in the literature for no studies have been done on MDR-TB risk
factors in the Philippines.
As shown in the graphs below, the incidence rate of TB in the Philippines continue
to decline from the year 2000 to 2014 and with a success treatment rate of 49%. (Figure
4).
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Figure 4. Incidence rate of TB in the Philippines from the year 2000 to 2014
Adopted from: Tuberculosis Country Profiles (WHO, 2014a).
The identification of risk factors for MDR-TB infection will lead into early
treatment prioritization and prevent the proliferation of TB disease in the community. In a
collaborative study by Bishai, Bishai and Bishai (2010), the researchers concluded that in
populations with low prevalence of drug-susceptible TB, a greater proportion of MDR-TB
case detection accompanied with compliance with directly observed treatment, shortcourse (DOTS) is crucial to prevent TB epidemic. The emergence of a new Mtb strains
and MDR-TB infection development could trigger an increase in TB prevalence rate in a
population that lost herd immunity. The study was performed through a computer
simulation of MDR-TB epidemics (Bishai et al., 2010). DOTS were developed by WHO,
as the most cost-effective strategy to stop the spread of TB. The treatment program is
based on five elements such as collaborative sustained effort from the government, case
detection, standardized treatment, regular, uninterrupted drug supply and a standardized
recording and reporting system for assessment of treatment result (World Health
Organization, 2014b).
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Importance for Social Change
The result of the study hopes to benefit the members of the community for it can
be used by public health practitioners as a basis in educating the population on risk factors
associated with the probability of MDR-TB infection that is relevant to the geographic
location. Geographically relevant risk factors may be significant for it may allow members
of the community to easily recognize and modify the situation so as to lessen the risk of
disease infection and ultimately reduce morbidity due to TB and MDR-TB.
The Philippines is considered a developing country where there are limited
resources. The reduction in MDR-TB transmission would result in reduced health care
costs as a consequence of decreased hospitalization admission of patients with MDR-TB.
Those limited resources can then be channeled to augment other needed health care
services for the population. Also, a decrease in MDR-TB transmission will lead to a
reduction in the bacterial reservoir within the community at large. Because the treatment
of the MDR-TB infection is expensive, knowledge of the risk factors associated with the
infection may prevent the disease occurrence in a family member and avert the burden of
its associated cost.
Health care providers will be able to prioritize diagnosis and treatment based on
risk factors knowledge which can save time, financial resources and most importantly
prevent further damage to patient's organ due to early detection and most effective
treatment. Another social impact of the study will be that it may help bring equity to the
underserved group especially that in most cases patients with tuberculosis belongs to
economically deprived segments of society.
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Summary
The Philippines MDR-TB infection ranks as ninth among the 22 highest TBburden countries in the world (Vianzon, Garfin, Lagos, and Belena, 2013). With limited
resources identifying the probable risk factors associated with MDR-TB infection needed
for patient early treatment prioritization and decrease the proliferation of the disease in the
community. The purpose of this study is to assessed the strength of association between
identified risk factors and the development of the MDR-TB infection in the Philippines.
Specifically, I examined whether the following factors are causally associated with MDR-

TB infection: (a) previous TB treatment, (b) infection with HIV, (c) exposure to a drugsusceptible TB/MDR-TB patient, (d) delay in diagnosis and treatment, (e) employment
status, (f) smoking, (g) imprisonment, (h) alcohol abuse, and (i) compliance with TB
treatment regimen. I conducted survey questionaire as primary instrument in obtaining
data from the study participants.
Chapter 2 of this research include the literature on TB pathogen MDR-TB,
characteristics, modes of transmission, pathogenesis of the bacterium; the organism’s
evolution from antibiotic susceptible to multidrug resistant, mechanism for drug
resistance,morbidity, mortality, and health cost are described in addition to clinical
presentation, signs, and symptoms to better understand the health impact of MDR-TB
infection. In addition, chapter 2 also provided MDR-TB geographic distribution,
manifestation, drug resistance, prevention, and control from published epidemiological
studies and the state of TB and MDR-TB epidemiology in the Philippines. Chapter 3 is an
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explination of the methods used to gather and interpret the data. Chapter 4 is a report of
the data and Chapter 5 is the interpretation of those data.
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Chapter 2: Literature Review
Introduction
The Philippines is a developing country and has one of the highest numbers of
MDR-TB cases and ranks as ninth among the 22 highest TB-burden countries in the world
(Vianzon, Garfin, Lagos, and Belena, 2013). The emergence of MDR-TB infection poses
a serious threat to TB control program of the Philippines government. MDR-TB infection
requires a longer period of treatment, and a result could consume the resources of the TB
control program. The study assessed the strength of association between identified risk
factors and the development of the MDR-TB infection in the Philippines. Specifically, I
examined whether the following factors are causally associated with MDR-TB infection:
(a) previous TB treatment, (b) infection with HIV, (c) exposure to a drug-susceptible
TB/MDR-TB patient, (d) delay in diagnosis and treatment, (e) employment status, (f)
smoking, (g) imprisonment, (h) alcohol abuse, and (i) compliance with TB treatment
regimen.
In this chapter, I provided a brief description and background of the TB pathogen
MDR-TB. The discussion includes the characteristics, modes of transmission, and
pathogenesis of the bacterium; the organism’s evolution from antibiotic susceptible to
multidrug resistant; and the mechanism involve for drug resistance. Morbidity, mortality,
and health cost are described in addition to clinical presentation, signs, and symptoms to
better understand the health impact of MDR-TB infection. I discussed current research
studies on risk factors of MDR-TB infection which served as background of the study
hypothesis.
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A discussion of MDR-TB geographic distribution, manifestation, drug resistance,
prevention, and control from published epidemiological studies are also presented. These
studies also provide the framework for my methodology. The section on the state of TB
and MDR-TB epidemiology in the Philippines was also discussed.
Literature Search Strategy
I used PubMed and Academic Search Premier databases to identify relevant
published research studies. Research from WHO and the journals New England Journal of
Medicine, Emerging Infectious Diseases, Clinical Infectious Disease, and Journal of
Infectious Diseases were used in the review of related literature. The research terms used
were multidrug resistance tuberculosis, Mycobacterium tuberculosis (Mtb), antibiotic
resistance, TB in the Philippines, and TB risk factors. Published studies from 2009 to 2014
were reviewed. The basis for the selection of published literature review inclusion are
those that discussed MDR-TB, tuberculosis, mycobacterium tuberculosis (Mtb), antibiotic
resistance, prevention and control, TB in the Philippines, TB epidemiology, disease
geographic distribution, prevention, control, clinical presentation, and risk factors
methodologies.
Pathogenic Characteristics of Mycobacterium Tuberculosis
General morphological characteristics of Mtb include being rod-shaped or tubercle
bacilli, slender, nonmotile, and appearing bent or curved (Gengenbacher & Kaufmann,
2012; Ahmad, 2011). The organism has an impermeable and thick cell walls or capsule.
The cell wall is composed of peptidoglycans, polysaccharides, unusual glycolipids, and
lipids. The lipids are made of a long chain of fatty acids, such as mycolic acid
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(Gengenbacher & Kaufmann, 2012; Ahmad, 2011). The organism belongs to the
mycobacterium genus and is known to be an opportunistic pathogen due to its ability to
survive in various types of environment (Cook et al., 2009).
Gengenbacher and Kaufmann (2012) found out that the ability of the Mtb
organism to become dormant in a nonreplicating state is due to low metabolic activity.
Dormancy in the nonreplicating state allows phenotypic drug resistance of Mtb. These
findings above were corroborated by Bret, Demetriadou, and Zahrt (2011), who found that
the Mtb organism adapts to changes in the granulomatous lesions environment. The
changes could be due to low-oxygen tension, nutrient depletion, reactive oxygen and
nitrogen species, altered pH, toxic lipid moieties, and cell wall/cell membrane-perturbing
agents. The adaptation is made possible through transcriptional reprogramming. In
transcriptional reprogramming, the original genetic expression that would not allow the
Mtb organism to survive in the unfavorable environmental condition leads to the
development of a variety of regulatory factors (Bret et al. 2011). Among these factors are
11 complete two-component signal transduction systems (TCSSs), several orphaned
response regulators (RRs), and sensor kinases (SKs) (Bret et al. 2011; Forrellad et al.
2013). Virulence genes develop that contain the code for the virulence factor protein
molecule which allows the Mtb organism to survive in the form of positive response to the
host immune reaction (Forrellad et al. 2013).
An important characteristic of this infectious agent of tuberculosis is that the
organism does not require specific nutritional substances for normal metabolism and
reproduction. The ability of the Mtb organism to survive in various types of nutritional
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substances provides ease of growth, proliferation and infection (Gouzy et al. 2013). The
flexible catabolic pathways allow multiple carbon and energy sources utilization from the
infected person to play a critical part in the mycobacterial physiology and virulence that
place TB disease as one of the global leading causes of morbidity and mortality (Gouzy et
al. 2013).
Furthermore, when bacteria infect the human body, the macrophage (a type of
white blood cell) engulfs and digests the microbe (phagocytosis) and initiates adaptive
immunity in conjunction with lymphocytes (Meena & Rajni, 2010). Mtb uses the
macrophage for its replication through various survival mechanisms, which then allows
the macrophage to remain available to host the pathogenic organism (Meena and Rajni,
2010). The survival mechanism could be through inhibition of phagosome harboring the
Mtb with a lysosome, acidification of the phagosome, protection from oxidative radicals,
TACO protein on the phagosome, and expression of virulence proteins in the PE-PGRS
family (Meena & Rajni, 2010). These Mtb survival strategies are comprehensively
described by Gengenbacher and Kaufmann (2012), who contend that the survival success
of Mtb is based on three capacities, which are first reprogramming of macrophages after
primary infection /phagocytosis in order to prevent its own destruction initiating the
formation of well-organized granulomas, second comprising different immune cells to
create a confined environment for the host–pathogen standoff; and third the capability to
shut down its own central metabolism, terminate replication and thereby transit into a
stage of dormancy rendering itself extremely resistant to host defense and drug treatment
(Gengenbacher & Kaufmann, 2012, p. 514).
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Meanwhile, one third of the global human population harbors Mtb in dormant form
(Guptaa, Kaula, Tsolakib, Kishoreb, & Bhakta, 2011). Considering this figure, public
health professionals should underscore the importance of addressing the issue on how to
prevent Mtb infection. WHO data showed that 1.3 million died from the disease in 2013,
of which 320,000 were HIV-positive individuals as a result of comorbidity (World Health
Organization (WHO, 2013a).
Modes of Transmission of Mycobacterium Tuberculosis
The mode of transmission for MDR-TB strains is the same to that of drugsusceptible Mtb organism strains. The primary mode of transmission of Mtb is through
inhalation of the tubercle bacilli that is present in the microscopic droplets from an active
TB infected person (Versalovic et al. 2011). The microscopic droplets of 1-5 micron in
size, once exhaled, easily mix with air circulation until a susceptible person inhales the
droplet nuclei (Versalovic et al. 2011). The expulsion of the microscopic droplets can also
potentially occur when an active TB-infected person coughs, sneezes, speaks, sings, or
laughs (NIAID, 2010a). However, not all persons exposed to microscopic droplets
containing Mtb bacilli develop tuberculosis. In fact, the risk of developing active TB
disease is only 10% for a person with a latent infection which is accelerated to 10-15% per
year to progression for patients with HIV (WHO, 2014d; Versalovic et al., 2011; Ritacco
et al., 2012).
Understanding disease transmission is one of the tenets of the science of
epidemiology. The proliferation of TB in a population can be prevented by understanding
the mode of transmission which can then be the foundation for the conceptualization and
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development of appropriate, correct proactive infection control measures. TB bacilli can
also be transmitted in a workplace as demonstrated in a study by Jonsson, Kan, Berggren
and Bruchfeld (2013).The researchers applied restriction fragment length polymorphism
technique to cluster the M. tuberculosis. The isolated organism was from healthcare
workers who develop TB within ten months after the death of an HIV-positive patient
with pulmonary tuberculosis. Study results showed that there was a correlation between
the number of working hours and risk of acquiring tuberculosis infection and disease.
Jonsson et al., (2013) recommended that healthcare workers should undergo screening for
latent TB as a baseline reference in case of future contact-tracing after an accidental
exposure. The aforementioned study exemplifies the occupational transmission modality
and is also present among dental hygienist. TB infection occurred among dental hygienist
after working for several months with patients coming from countries in which TB is
endemic (Merte, Kroll, Collins, and Melnick, 2014).
Though social interaction has shown to contribute the transmission of Mtb,
physicochemical environmental parameters likewise play a role in the proliferation of the
microscopic droplets that contain the Mtb bacilli. The observed cause of the seasonal rise
of tuberculosis during winter is crowding. This was affirmed by a study performed from
1993 to 2004 in the Netherlands (n = 4,746) using autocorrelation function plots and
spectral analysis. The researchers found out that the increased transmission of TB during
winter time is unlikely to be the only cause of the seasonal peak in TB notifications
(Soetens, Boshuizen, and Altes, 2013).
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Whenever human overcrowding occurred due to limited space; the situation is a
potential, excellent ground for Mtb proliferation especially when an infected person in the
group coughs. López et.al, (2013) performed a study to evaluate the use of coughgenerated aerosols of M. tuberculosis to predict recent transmission. Multivariable logistic
regression analysis with cluster adjustment was applied to analyze predictors of new
infection among patients with pulmonary TB. The respondents of the study underwent a
standard evaluation and collection of cough aerosol cultures of M. tuberculosis. The study
data revealed that household contacts of patients with TB who produced high aerosols
(≥10 CFU) were more likely to have a new infection compared with contacts of TB
patients with low-aerosol (1-9 CFU). , Patients with a high TB aerosol contact was the
only predictor of new M. tuberculosis infection in unadjusted and adjusted analyses. The
importance of identifying the reservoir of TB transmission within the community deserves
increased focus. This could be done by intensive household contact tracing to attain an
effective disease transmission reduction (Kompala, Shenoi, and Friedland, 2013).
In the continental United States, about a fifth of MDR-TB cases can be linked to
transmission within the country. The disease reservoir is infected person who already
acquired TB before entry into the country (Moonan et al., 2013).The data from this case
finding study showed that 20 (22%) of these individuals developed MDR-TB as a result of
the transmission within the country. The researchers found out that 38 (41%) were deemed
to have reactivation of disease. However 14 (15%) respondents had a known previous
episode of tuberculosis outside the USA; five individuals (5%) had documented the
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treatment of the previous episode, and nine cases (10%) insufficient evidence to
definitively classify reason for disease transmission (Moonan et al., 2013).
It is then apparent that there is a need to fully understand the risk factor for
communicable disease transmission to develop a disease transmission control program
like those geared for MDR-TB. Such program could be community-based treatment.
Community-based treatment program offers important advantages over the hospital or
clinic-based care not only in cost and effectiveness. It allows rapid identification of
infectious cases especially in drug-resistant cases, followed by effective and fully
supervised treatment (Nardell and Dharmadhikari, 2010).
The study by López et al., (2013) suggested that Mtb transmission is better
predicted in cough aerosols than sputum smear microscopy or culture. Close and frequent
proximity to TB-infected persons that coughs are an excellent mode of Mtb transmission.
The finding above is further corroborated in a study by Kopeć et al., (2012). The
researchers studied 35 family households in Poland using spoligotyping and the
mycobacterial interspersed repetitive unit-variable-number of tandem repeat (MIRUVNTR) typing. Results of the study demonstrated that out of 78 patients, 49 (63%) of the
infection was attributed to intra-household transmission. The finding clearly supports the
study conclusion of López et al., (2013) that household setting is an important reservoir of
Mtb transmission.
DRUG-RESISTANT TUBERCULOSIS
History of drug resistance
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Tuberculosis has almost threatened the very existence of humanity in the
biosphere. Since the time, immemorial this white plague has caused the loss of millions of
lives. The discovery and development of streptomycin in 1944 paved the way for the
treatment of TB infected person. The treatment was considered as the first world drug trial
involving randomization of study participants (Keshavjee and Farmer 2012). However,
resistance to the first anti-tubercular drug became apparent as shown by some patients
with relapse. Laboratory tests showed that the bacilli from the sputum of that patient were
resistant to streptomycin due to a mutation in the 16S ribosomal DNA (rrs) and the S12
ribosomal protein gene (rpsL). The resistance was attributed to the drug mechanism target
of disrupting the bacterial protein synthesis (Goldberg, Siliciano, and Jacobs, 2012).
Since then, research on new antitubercular medication has lead to the development
of isoniazid, pyrazinamide, cycloserine, ethionamide, rifampin, and ethambutol. Drug
resistance always threatened the effectiveness of the monotherapy due to Mtb selective
mutation (Keshavjee and Farmer 2012). Antibiotics currently available for TB treatment
act differently on Mtb. As shown in Figure 5, the synthesis of Mtb cell wall is inhibited by
isoniazid and ethambutol. Rifampin inhibits the synthesis of RNA and pyrazinamide
antibiotics prevent the microbial growth by disrupting the plasma membrane and energy
metabolism (NIAID, 2012b).
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Figure 5. First-Line Treatment of Tuberculosis for Drug-Sensitive TB. Courtesy
National Institute of Allergy and Infectious Diseases. Adopted from: NIAID, (2012b).

Recognizing the potential for antibiotic resistance, combining anti-TB drugs or
multiple drug chemotherapy became the standard of treatment specially that drug
resistance has received increased attention in the early of 1990's since TB became a comorbidity of Human immunodeficiency virus- immunodeficiency syndrome ( HIVAIDs).A typical example was the study on modeling the dynamic relationship between
HIV and the risk of drug-resistant tuberculosis by Sergeev, Colijn, Murray, and Cohen
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(2012). The researchers concluded that the rise in HIV could increase the prevalence of
MDR-TB in populations due to preferential social mixing among individuals.
Classification of Drug Resistance
The emergence of MDR-TB undermines the effort of the World Health Organization
through the Millennium Development Goals (MDGs) and by the Stop TB Partnership. The
programs aim to reduce by 50% TB prevalence and death rates towards the end of 2015
and to eliminate TB as a public health problem by 2050 (WHO, 2014e). The current
epidemiological standard for MDR-TB classification is provided in the World Health
Organization Guidelines for surveillance of drug resistance in tuberculosis – 4th ed. The
treatment regimen survey aims to determine the predominant source and pattern of MDRTB. The source of the classification provides a clear definition of patient's registration
groups by the history of previous treatment. The classifications are a new case, previously
treated case, primary resistance, acquired resistance, cured and failed (WHO, 2009).
Mechanism of Drug Resistance
The mechanism of Mtb drug resistance has been studied using molecular genetics
approach. Understanding the mechanism involved in drug- resistance is critical in the
development of new anti-TB medicine besides the fact that the presence of drug resistance
Mtb compounds the problem of eliminating TB. Mtb drug resistance could be
intrinsic/natural or acquired. The natural presence of an unusual structure of the mycolic
acid-containing cell wall allows a low permeability of chemotherapeutic compounds such
as antibiotics on top of the role of efflux mechanism (Da Silva and Palomino, 2011). This
was further substantiated by an in vitro induction study that aimed to investigate the
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mechanism by which resistance towards isoniazid develops and how overexpression of
efflux pumps favors mutations development in isoniazid targets (Machado et al., 2012).
The aforementioned study applied a prolonged serial exposure of Mtb strains to the critical
concentration of isoniazid. The study revealed that susceptible and rifampicin monoresistant strains once exposed to this concentration become resistant to isoniazid after
three weeks, and that resistance observed for the majority of these strains could be reduced
using efflux pumps inhibitors due to overexpression efflux pump genes. Machado et al.,
(2012) further provided justification that intrinsic or natural resistance, as exemplified by
the efflux, pumps mechanism allows the maintenance of an isoniazid-resistant population
in a sub-optimally treated patient.
The repeated and inappropriate use of antibiotic is a major cause of acquired
antibiotic resistance. The resistance may also develop as a result of chromosomal
mutations wherein the number of chromosomes or the bacterial structure is changed or
through horizontal gene transfer that involves the alteration of the original genetic code
(Smith, Wolff, & Nguyen, 2013). The chromosomal mutation was examined by
Georghiou et al., 2012. The researcher made use of published studies to determine Mtb
mutations association with resistance to Amikacin (AMK), Kanamycin (KAN),
Capreomycin (CAP) antibiotics. Further, the researchers also characterize the diversity
and frequency of mutations as well as describe the strength of the association between
specific mutations and phenotypic resistance in global populations. The researchers found
out that genes rrs A1401G mutation were present in the majority of AMK, KAN, and CAP
resistant Mtb strains, but was also found in 7% of CAP susceptible strains (Georghiou et
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al., 2012). Isoniazid and Rifampicin are the common first line of drug in the treatment of
tuberculosis. The Mtb genes involved in acquired antibiotic resistance to isoniazid are
katG, inhA, ndh, and ahpC which function for prodrug activation, drug target, and activity
modulation and resistance marker respectively. Likewise, rpoB gene reacts on drug target
and is involved in rifampicin resistance (Smith, Wolff, &Nguyen, 2013)
Epidemiology of Drug Resistance Tuberculosis
The MDR-TB infection has spread globally. This was observed since the
introduction of the first anti-tuberculosis drug streptomycin in 1944. Microbial culture of
patients that underwent relapse of the disease showed resistance to the antibiotic
(Keshavjee, and Farmer, 2012). WHO in 1994 initiated the Global Project on AntiTuberculosis Drug Resistance Surveillance. The program systematically collected and
analyzed data from 114 countries WHO, 2010a). The 2010 surveillance data of countries
(see Table 1) that reported first-line anti-TB drug resistance show the highest level of
resistance is in Europe. A total of 44 countries or 83% reported first-line anti-TB drug
resistance out of 53 European countries monitored. South-East- Asia where the
Philippines is located, ranks third with six countries out of 11 (55%) reporting first-line
anti-TB drug resistance. In this year alone, the global proportion of MDR-TB among new
TB cases reported ranged from 0-28.3% (WHO, 2010a).
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Table 1
Number of Countries Reporting Data on Resistance to First-Line Anti-TB drugs by WHO
Region

Note. Republished from Multidrug and extensively drug-resistant TB (M/XDR-TB)
2010 Global Report on Surveillance and Response. Copyright 2010 by the
World Health Organization.
The proliferation of this disease especially MDR-TB is of grave concern to public
health for it transcends borders, thus potentially undermines if not reverses the
achievement of TB control and eradication led by WHO. Moreover, the treatment of
MDR-TB is difficult and complex when compared to that of drug-susceptible TB. It takes
up to two years, involving daily injections of very toxic medicine for six months, and is
significantly more expensive. The cost associated with MDR-TB treatment imposes a
significant challenge to the government health care system and especially to vulnerable
low income families (Tuberculosis Alliance, 2014). Besides the social stigma associated
with the disease that destroys families, the productivity loss attributable to TB is 4 to 7
percent of the Gross Domestic Product (Tuberculosis Alliance, 2014).
It is within this framework that the National Strategy for Combating Antibiotic
Resistant Bacteria was initiated last September 2014 by the United States Government.

34
The initiative is a bold step to slow the global public health threat of antibiotic-resistant
bacteria typical of which is MDR-TB. The initiative will be achieved in collaboration with
the international communities among which is the Trans-Atlantic Taskforce on
Antimicrobial Resistance and WHO Global Action Plan for Antimicrobial Resistance. The
first two goals of the plan were to: (1) slow the emergence of resistant bacteria and
prevent the spread of resistant infections, (2) strengthen National One-Health surveillance
efforts to combat resistance (U.S. Government – White House, 2014). Antibiotic
resistance is a threat to public health and the economy. In the United States of the 9,588
TB cases reported in 2013, it was estimated that 1-2% has MDR-TB. The treatment cost
per case based on the 2010 dollar value is $134,000(U.S. Government – White House,
2014).
Geographical prevalence of MDR-TB transcends country's economic and health
care system condition. The drug resistant organism could easily be introduced and
proliferate from one country to another especially now a day that people can easily travel
because of the modern mode of transportation. The most recent global surveillance data,
as shown in Figure 6, percent of new MDR-TB cases in some parts of the former Soviet
Union have reached 18 percent, and in the Philippines, the percent of new cases is at 3 to
5.9 percent (WHO, 2013a). More than 80% of those who contracted MDR-TB in North
America and Europe died; today the disease is now common in India and China.
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Figure 6. Percentage of new TB cases with MDR-TB, 1994-2012. Adapted from: WHO,
(2013)
MDR-TB affects a person of any age, and one of the most MDR-TB vulnerable
population groups are children under 15 years of age. The World Health Organization
drug resistance surveillance data between 1994 and 2011 were analyzed to test the
association between MDR-TB and age group by Zignol et al. (2013) using odds ratios
derived by logistic regression. The odd ratio of MDR-TB in children compared to adults
varies between countries. In Germany, Namibia, South Africa, the UK and the USA,
children <15 years appear to be at significantly higher risk for MDR-TB. The researchers
concluded that of the risk of MDR-TB in children and adults are similar in many settings.
This finding was later supported by a recent study that aimed to quantify the global
incidence of MDR-TB disease in children (Jenkins et al., 2014). Results of the study data
after statistical analysis showed that the risk of MDR-TB was nearly identical to children
and adults since both groups are exposed to the same local risk. In this meta-analysis
study, the researchers considered 3,403 published research studies, of which only 97
studies met inclusion criteria. Statistical calculation of the risk estimated around 1,000,000
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(95% Confidence Interval: 938,000 –1,055,000) children developed TB disease in 2010,
among whom approximately 32,000 (95% Confidence Interval: 26,000 – 39,000) had
MDR-TB (Jenkins, et al, 2014).
RISK FACTORS FOR MDR-TB AND METHODS USED IN THE STUDY
Identification of risk factors is critical since it serves as the foundation for the
development of disease prevention and control strategy program. Because of their
fundamental role, the identified risk factors should be a result of scientifically based
evidence of causality (Porta, 2014). Health risk factors related to MDR-TB increase the
chance of getting the disease; nevertheless, it does not imply that the person exposed to
such identified risk factors will develop the disease. What is significant to know if
preventive care was received after exposure to the risk factor. Preventive care has
demonstrated to be very valuable in early disease detection and infection proliferation
control among the population especially for a transmittable disease like MDR-TB.
Various risk factors for MDR-TB have been identified depending on the intent of
the study and respondents geographical location. Risk factors for the MDR-TB infection
are influenced by sociobehavioural, demographic, and economic condition prevailing in
the study area coupled with the respondent’s current health condition. In a meta-analysis
study done by Zhao, Li, Zhang, Wang and Liu (2012), evaluation and analysis of 16
studies obtained from PubMed and Chinese BioMedical databases was performed. MDRTB was significantly associated with poor quality of Directly Observed Treatment Shortcourse, poor treatment adherence, previous treatment, poverty, and age. The findings were
a result of selected published articles that were independently reviewed following certain
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inclusion criteria, and the data were analyzed using Review Manager Software. In a
similar study done in the eastern part of China, the case-control study design was utilized
to determine the risk factors for MDR-TB among previously TB treated patients. Preidentified TB patients resistant to at least isoniazid and rifampin were classified as cases,
and those, who are susceptible to the TB drug, were under the control group. Multivariate
analysis of data showed that the risk factor associated with MDR-TB is the previous
treatment of TB (Chen et al., 2013). The treatment course for TB sometimes takes a longer
period providing a great chance for the patient to comply poorly with the prescribed
treatment regimen. Liu et al. (2013) conducted a similar study in Northeastern China. One
of the inclusion criteria in the study was that the sputum collected from the respondent
should show positive for the presence of Mtb bacteria in addition to being a resident of
Lianyungang City. Besides the laboratory report, other data were obtained from personal
information, physical examinations, present illness, TB-related complaints, previous
medical history, family history and the purified protein derivative test (skin test) result
(Liu et al.,2013). The data were obtained through interview and review of respondents’
medical records (Liu et al., 2013). Using SPSS version 13.0 data were stored and analyzed
to determine the probable association between selected factors. The odds ratios and 95%
confidence intervals from an unconditional logistic regression model with P < 0.05 based
on a two-sided test was applied as the criterion for significance (Liu et al., 2013). The
researcher found a similar result that previous treatment classified as the first treatment of
more than eight months and more than three prior episodes of anti-TB treatment was an
important risk factor for the MDR-TB infection.

38
Van der Wef, Langendam, Huitric and Manissero (2012) performed a metaanalysis of studies published from the database in MEDLINE and EMBASE on drug
resistance after inappropriate TB treatment. The study aimed to assess the evidence that
inappropriately following the prescribed tuberculosis treatment regimen is a risk factor for
the development of MDR-TB. The researchers found out that there was not enough
evidence that MDR-TB development is caused by inadequate treatment. One of the studies
that were reviewed showed a 27 fold increase of developing MDR-TB in patients who
failed treatment when compared to those patients that observed appropriate treatment
regimen (Van der Werf et al., 2012). What is significant in studies done by Zhao, et. al.,
(2012) and Chen et al. (2013) was that their results underscore the importance of a highquality standard antibiotic treatment and a strict follow-up of patients to ensure adherence
to the prescribed regimen. This is done to avoid possible mutation or evolution of the
organism into drug-resistant strain otherwise exposure to TB treatment becomes a risk
factor for the development of drug-resistant organisms.
In addition to poor quality of previous TB treatment, gender, and age other
contributing risk factors for MDR-TB were also ascertained by Rifat et al. (2014). MDRTB patients, who are the subject of the study, were randomly selected from government
hospitals located in urban and rural areas of Bangladesh. The researchers applied the casecontrol study design wherein the drug-susceptible TB patients (N = 750) are in the control
group while the MDR-TB patients (N = 250) are the cases. All recruited study respondents
were of confirmed diagnosis for MDR-TB. A face-to-face interview using a structured
questionnaire, and clinical record reviews were conducted to obtain socio-demographic
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information to develop the database. The questionnaire was designed to obtain data on
possible risk factor association on predictors such as the previous history of TB treatment,
gender, age group, education, occupation, smoking status, substance misuse and presence
of type-2 diabetes. Data was analyzed using unadjusted and multivariable logistic
regressions. Results of the study showed similar strong association (Odd Ratio 716.6, 95%
Confidence Interval 282.1-1820.8) of previous TB treatment history with that conducted
by Liu et al. (2013). Previous TB treatment history was predominant (98%) among MDRTB patient respondents in this study compared to drug-susceptible TB patients (6.4%).
Other risk factors associated with MDR-TB infections in the following decreasing order of
association are; age, education, service, business as occupation, service and business as
occupation and type 2 diabetes (Rifat et al., 2014).
Type 2 diabetes is not the only identified comorbid illness identified as the risk
factor associated to MDR-TB but also the presence of Human Immunodeficiency Virus
(HIV) infection. Skrahina et al. (2013) conducted a survey study in Belarus wherein one
of the study aim is to ascertain the risk factor for MDR-TB proliferation in the country.
Respondents of the study were not classified between cases and control. The two sputum
samples submitted by respondents were subjected to acid-fast direct microscopy
examination, and the other was cultured to determine drug resistance or susceptibility.
Proper treatment was provided to the respondents. Structured questionnaire interview was
applied to gather information on sociobehavioural, treatment history, demographic
characteristics, education, living and employment conditions, history of imprisonment, use
of alcohol, smoking and HIV infection (Skrahina et al., 2013). Data analysis generated
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from the EpiInfo software package version 3.5.1 wherein all the information were stored
and statistically subjected to Pearson X2 to compare categorical variable. Analyses showed
that previous treatment history was the number one risk factor for MDR-TB infection. The
Odds Ratio was 6.1; 95% Confidence Interval: 4.8–7. This was followed by the presence
of HIV infection with Odds Ratio: 2.2; 95% Confidence Interval: 1.4–3.5 (Skrahina et al.,
2013). The researchers considered the possible risk factor to be associated with the MDRTB infection if the P-value is <0.05. Statistical analysis revealed that in Belarus, the risk
factors for the MDR-TB infection are age < 35 years, history of imprisonment, disability
sufficient to prevent work, alcohol abuse and smoking (Skrahina et al.,2013).The result of
the study perhaps indicates that the convergence of HIV and MDR-TB infections is of
great public health concern. This requires a stronger collaboration between the two disease
control programs and most importantly acceleration of TB resistance detection and
improvement to treatment adherence.
HIV as a risk factor for the MDR-TB infection was found to be similarly
correlated in a study done in Hanoi, the capital of Viet Nam (Hang et al., 2013). Clinical
and epidemiological information were collected by the researchers in this study from 506
newly diagnosed patients with sputum smear- and culture-positive TB. Data were
subjected to adjusted odds ratio analysis to determine risk factors degree of correlation to
drug resistance. Interesting in this study was that the researchers aimed to understand the
risk factor associated with TB drugs (isoniazid, rifampicin streptomycin, and ethambutol)
resistance and multi-drug resistance from the Mtb. TB drug resistance test was performed
on isolates cultured from respondent’s sputum. Study result showed that risk factors
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associated with isoniazid resistance include living in old urban areas, the presence of the
Beijing genotype, and clustered strains. Patient with the Beijing genotype strain of Mtb is
resistant to streptomycin (Adjusted Odds Ratio: 2.10, 95% Confidence Interval; 1.29–
3.40). Moreover, HIV co-infection was found to be associated with rifampicin resistance
and MDR-TB (Hang et al., 2013). The researchers of the study concluded that Mtb drugresistant strains could be avoided based on the result of drug susceptibility, coupled with
monitoring to ensure treatment prescription adherence.
The identification of risk factors can also be studied following a descriptive case
series study design, wherein data are obtained through structured interview and abstraction
of treatment record from patient (Pant et al., 2009). In this study, the data was gathered
within eight months period from respondents in a DOTS-Plus clinic at Bhim Hospital,
Bhairahawa. The study did not have a case-control. However, the authors found out that
the primary risk factors for MDR-TB are previous TB treatment followed by male sex,
poverty, migration to India, illiteracy, and smoking (Pant et al., 2009).
The literature review showed that varying study design and data gathering strategy
could be applied to determine the risk factor of MDR-TB. Terlikbayeva et al., (2012)
applied correlational and descriptive analyses to determine the MDR-TB risk factor and its
temporal and spatial distribution in Kazakhstan. This study considered social, economic
and environmental factors as possible determinants of drug-susceptible TB and the MDRTB infection. Specifically, the researcher analyzed the TB surveillance data from the
National Institute of Geography (NIG) and the National Tuberculosis Program (NTP). The
analysis centers on the possible association of MDR-TB infection of alcohol use,
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vulnerable group, the presence of diabetes, drug use, jail history, migration status, TB
treatment history, occupation, exposure to TB patient, and if recent mother. The data were
subjected to descriptive statistical analysis using Microsoft Excel 2010 and SAD 9.2.
Thou correlation analysis was not applied in this study; the researchers found out that
most study respondents with the MDR-TB infection had previous contact with the patient
with drug-susceptible TB or MDR-TB (Terlikbayeva et al., 2012). In addition, the study
demonstrated that MDR-TB cases increase in Kazakhstan as the prevalence rate of drugsusceptible TB decrease thereby threaten the gain in the TB control program.
The proliferation of MDR-TB within the household or community as a result of
social interaction, behavior, demographic and health conditions has been observed in
studies. Cohen et al., (2011) using spoligotyping and 24-loci mycobacterial interspersed
repetitive unit–variable number tandem repeat to classify isolates from 101 households in
Lima, Peru wherein >1 MDR-TB patient received treatment from 1996–2004. The
primary purpose of the study was to estimate the frequency of multiple introductions of
MDR-TB into households. The researcher made use of genetic marker to track Mtb
organism. Data showed ≥ 10% of households are re-infected with the same MDR-TB
strain, and 4% are from different MDR-TB strains. Interestingly the proliferation of MDRTB in a community could be brought about by migrants who have been exposed to
resistant Mtb strains, and possibly inadequate TB treatment (Bojorquez et al., 2013). This
was the findings of Bojorquez et al., (2013) wherein data from Mexico's National TB
Drug Resistance Survey (2008-2009) was subjected to multivariate analysis. Factors
associated with MDRTB are previous anti-tuberculosis treatment, Mexico-born TB
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patients in California and those born elsewhere had greater odds of MDR-TB infection
compared with patients who were born in the US (Bojorquez et al., 2013).
CLINICAL PRESENTATION OF TB AND MDR-TB
There is no difference in the clinical presentation of MDR-TB with that of drugsusceptible TB. A bad cough that last three weeks or longer, pain in the chest, coughing
with blood or sputum (phlegm from deep inside the lungs), weakness or fatigue, weight
loss, no appetite, chills, fever, sweating at night are the general symptoms of the disease
(CDC, 2012). Other respiratory symptoms may include shortness of breath, chest pains,
and hemoptysis (WHO, 2010b).
To rule out the possibility that a patient may be infected, various diagnostic tests
are available. Some active TB-infected patient' do not exhibit respiratory symptoms thus
the application of chest x-ray is a valuable tool to identify the presence of pulmonary
lesions that may indicate the presence of the disease. However, the most definitive means
of diagnosis are through culture collection from three-morning sputa. Culture collection of
Mtb bacteria is considered the “gold standard” for TB diagnosis (WHO, 2010b). On the
other hand, patients with latent TB infection can be tested using tuberculin skin testing as
indicated by 5 mm induration two to three days after intradermal injection of M.
tuberculosis antigens (Konstantinos, 2010). Clinical symptoms of TB vary especially
those with extra-pulmonary TB located in lymph nodes, kidney, bones, and brains making
it difficult for diagnosis and monitoring treatment progress (Zhang et al., 2011).
Since symptoms of MDR-TB and drug-susceptible TB are not different this,
becomes difficult for clinicians to diagnose and prescribe the appropriate chemotherapy
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without a definitive identification and characterization of the organism collected from the
patient sputum. The Food and Drug Administration (FDA) permitted marketing of the
Xpert MTB/RIF assay instrument (Cepheid, Sunnyvale, California) to detect DNA of the
Mtb complex (MTBC).The instrument can determine genetic mutations associated with
resistance to rifampin (RMP) in unprocessed sputum and concentrated sputum sediments.
Test results generated by the instrument in conjunction with clinical, radiographic, and
other laboratory findings will provide clinicians a comprehensive assessment in the
diagnosis of pulmonary tuberculosis (CDC, 2013).
TUBERCULOSIS IN THE PHILIPPINES
The Philippines with a developing economy located in the south-eastern part of
Asia composed of 7,107 islands. Based on the 2010 population census data, there are 92.3
million Filipinos (Vianzon et al., 2013). Based on 2010 national data the Gross Domestic
Product grew by 7.3%. The geographical location of the country is along the Pacific Ring
of Fire and typhoon belt. A significant number of people are displaced and killed due to
several natural disasters that occurred in the country (WHO Western Pacific Region,
2014). Natural disasters are some of the risks that hinder the steady rate of Philippines
development; thus the significant proportion of the population remain poor (WHO
Western Pacific Region, n.d.a). Other health-related risk factors cited by the WHO
Western Pacific Region are air pollution, water pollution, poor sanitation and unhygienic
practices and solid waste mismanagement. Further, low-income families living in isolated
areas are faced with difficulties going to health centers and schools due to inadequate
infrastructure and economic condition. The HIV prevalence in the Philippines though
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under 0.1% is rapidly expanding due to men who have sex with men, and injection drug
users. Besides Tuberculosis, other diseases prevalent in the country are malaria, dengue,
filariasis, leptospirosis, other diarrheal diseases, and some soil-transmitted helminths
(WHO Western Pacific Region, n.d.). The diseases above are endemic nationwide.
Smokers comprise 28.3% of the adult population based on 2009 Global Adult Survey
conducted in the country.
TB mortality remains high at 27 per 100,000 populations. TB disease is the sixth
leading cause of morbidity and mortality in the Philippines. The country is ninth out of the
22 highest TB-burden countries (WHO, 2014f). The TB disease-causing organism was
classified as Manila family of Mtb and is a group of clonal isolates seen throughout the
Pacific Basin (Frink et al., 2011). TB case notification rate in the Philippines of positive
smear cases from 2003 to 2011was highest in 2006 per 100,000 and experienced a decline
from 2007 to 2008. An increase observed from 2009 to 2011 but a little below the 2006
case notification rate (Vianzon et al., 2013). The awareness about the disease is present,
but the level of understanding of what causes the disease, how it is transmitted, and the
importance of completing the prescribed treatment is small (PhilPact, 2010-2015).
A literature review of published studies showed a possible gap of MDR-TB risk
factor association studies in the country. One such study is a nationwide survey conducted
in the Philippines with respondents enrolled from June 2003 to November 2004 following
population-proportionate cluster sampling. The study primary purpose was to determine
the national level of MDR-TB prevalence against the isoniazid, rifampicin, ethambutol
and streptomycin (Philippine Nationwide Tuberculosis Drug Resistance Survey Team,
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2009). The study was conducted for 17 months. The demographic characteristics obtained
are; age, gender, place of residence (Philippine Nationwide Tuberculosis Drug Resistance
Survey Team, 2009). This comprehensive study made use of the Epi Info Version3
software for data storage and in the determination of drug resistance prevalence. What is
remarkable in the study was that previously treated cases had 38.8% resistance to the four
drug identified. The percentage resistance is higher to the 20.4% resistance from not
treated or new cases throughout the country (Philippine Nationwide Tuberculosis Drug
Resistance Survey Team, 2009). In addition, most of the respondents, that has been
previously treated, were resistant to isoniazid followed by rifampicin, streptomycin and
least resistant to ethambutol (Philippine Nationwide Tuberculosis Drug Resistance Survey
Team, 2009).
On the other hand, isoniazid was still observed as the antibiotic of primary
resistance for new cases followed by streptomycin, rifampicin, and ethambutol (Philippine
Nationwide Tuberculosis Drug Resistance Survey Team, 2009). Remarkably the findings,
where Mtb was most frequent drug resistant to isoniazid, was concurred in a study that
was done on wider year coverage from 2003-2008. The later study found out that among
new TB cases, most drug resistance pattern is isoniazid and rifampicin. The anti TB drug
resistance pattern in the country was primarily isoniazid followed by rifampicin with
fluoroquinolones (Gler, Guilatco, Guray & Tupasi, 2012). The findings from the studies
above are of great concern to a public health practitioner. Clinicians’ selection for
antibiotic to treat the disease will be limited. Antibiotic susceptibility testing, to determine
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the most effective drug that will eliminate the pathogenic organism, will add burden to
patients.
The treatment of TB provides an additional economic burden on the country's
health care system. Fitzpatrick, & Floyd (2012) reported that treatment cost of TB patient
in the Philippines is $US3, 613. The country a gross national income as of 2003 data is
only US$1, 080. MDR-TB treatment cost is more expensive since the drug used for
treatment is considerably higher than drug-susceptible TB cases. Nevertheless, the overall
cost of MDR-TB treatment in the Philippines is still lower when compared to other
European countries (Loddenkemper, Sotgiu & Mitnick, 2012).
Significantly the transmission of this communicable disease in the Philippines does
not necessarily occur directly from the patient living in close proximity in the same
household but rather frequently is community-based (Sia et al., 2013). The rapid
proliferation of the disease not only affects the lungs but as well the eyes that add a burden
to the patient and decreases economic productivity. Seven out of the 103 pulmonary TB
patients in the Philippines (6.8% prevalence: 95% CI 2.78% to 13.5%) showed signs of
ocular inflammation and lesions (Lara, and Ocampo Jr, 2013).
TB treatment in the Philippines is provided free of charge in government hospitals.
This does not include another incendiary cost such as transportation to clinic or hospitals,
food, etc. Besides other cost associated with treatment, socio-ecological barriers to
treatment can be a factor for the disease to spread within the community. Among which
are the quality of healthcare services provided, shame associated with TB and familial
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responsibility accompanying during the treatment period (Hua, Loob, Wincha, &.
Surkana, 2011).
The need to control if not stop the proliferation of the disease does not center only
on the detrimental effect on the physiological health of the infected person but likewise on
the mental health brought about by depression. In a cross-sectional survey conducted
among pulmonary TB-infected patient that live in Tondo, Manila Philippines16.8% out of
the 561 respondents manifested depressive state (Masumoto et al., 2014). The Philippines
government recognizes the detrimental effect of TB to health and the economic burden
that the disease brought about to patient and society as a whole. TB Control Program was
initiated in the Philippines following guidelines provided by the World Health
Organization in which free treatment is provided through Directly Observed Treatment,
Short-course (DOTS). The treatment program is managed by the National TB Control
Program (NTP) of the Department of Health which develops policies and plan. The
program was implemented in a devolved system down to the lowest structure of
government starting from the national, regional, provincial, municipal and finally
Barangay level through a standardized reporting system (Vianzon et al., 2013). However,
because of budgetary requirements electronic surveillance to develop a central data system
is not yet fully implemented in the country; thus most clinical case record can be obtained
through identified DOTS centers. Because of MDR-TB threatens the gains achieved in
drug-susceptible TB control program through DOTS; the public-private partnership was
forged, and the incorporation of MDR-TB services into the NTP was required by the
Department of Health (Quelapio et al., 2010).
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Chapter 3: Research Method
The study objective was to assess the strength of the association between possible
risk factors and development of the MDR-TB infection. Possible risk factors (the
independent variables) that were considered in this study were (a) previous TB treatment,
(b) HIV infection, (c) exposure to a drug-susceptible TB/MDR-TB patient, (d) delayed
diagnosis and treatment, (e) employment status, (f) smoking, (g) imprisonment, (h)
alcohol abuse, and (i) compliance with drug-susceptible TB treatment regimens. I hope
that study results provide a basis for public health professionals and other community
stakeholders to develop effective and proactive intervention programs to enhance the
prevention of MDR-TB in the Philippines.
In this Chapter, I provide an overview of the research design I used, which
includes specific details regarding the method, study population, sample, and sampling
strategies. The relationships between the study variables are also explained in this chapter.
Furthermore, I provide a presentation of the statistical treatment of data and ethical
considerations regarding protection of study participants.
Research Design and Rationale
The study applied a quantitative method to assess the strength of the preidentified
possible risk factor(s) associated with MDR-TB infection. The data that e collected was
assessed to provide evidence of causality. Specifically, case-control design was used in the
study. The study subjects were patients who had been clinically confirmed to be MDR-TB
positive. MDR-TB infection was the dependent variable of the study.
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The control subjects were selected among patients with drug-susceptible TB and
clinically confirmed patients with MDR-TB are the cases. Age, gender, and education of
control subjects were matched with cases to minimize the effect of confounding. The
survey questionnaire is the primary instrument for obtaining data from study participants.
Prior research studies performed by Chen et al. (2013) and Rifat et al., (2014)
demonstrated that relevant potential risk factors for MDR-TB infection in a particular
geographic location could be well studied using a case-control design. I identified risk
factor variables to use as independent variables based on the literature I reviewed in
Chapter 2.
Settings and Samples
The control and possible eradication of MDR-TB in the Philippines is managed by
the Department of Health National - Center for Disease Prevention and Control through
the National TB Control Programme (NTP). The central NTP team develops policies,
standards, and plans and offers guidance for regional, provincial, municipal, and Barangay
levels of government. The primary purpose is to ensure standardized routine treatment of
patients through the Directly Observed Treatment, Short-course (DOTS) at designated
facilities to control the proliferation of the disease (Vianzon et al., 2013).
Based on geographical location and accessibility of clinics and hospitals, I
recruited target survey respondents from Programmatic Management of Drug-Resistant
(PMDT) TB clinics and hospitals and drug-susceptible respondents from town health
centers that provide DOTS as designated by the National Tuberculosis Program to treat
MDR-TB and drug-susceptible TB patients. Most of the 2,618 MDR-TB patients
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nationwide are treated in PMDT clinics located in metro Manila (Philippine Business for
Social Progress, 2013). One of the PMDT centers is the San Lazaro Hospital, which is
located in Manila. A municipal health clinic from the town of San Mateo, Rizal, was also
a source of MDR-TB cases, and most of the controls were recruited from the different
towns of the province of Leyte such as Burauen, Dagami, Tanauan, Barugo, Capoocan,
and Carigara. Leyte is part of Region VIII in the Eastern Visayas Island, which is my
home region.
Population Inclusion and Exclusion Criteria
The primary inclusion criteria of the respondents in the case group was that the
respondent’s has a documented medical record that M. tuberculosis was detected in
patient's sputum, and the microbial strain is resistant to either isoniazid or rifampicin.
Bacterial resistance to antibiotic is determined through drug susceptibility testing
(Philippine Department of Health -National TB Control Program, 2014). The primary
inclusion criterion for the control group was that the respondent has a confirmed
documented medical record indicating the identification of Mtb from the patient’s sputum.
However, microscopic sputum examination for the presence of Mtb may affect the
performance characteristics of the control due to potential unrecognition of drug resistant
Mtb. This was demonstrated in a study performed by Singh (2014) wherein the sputum
microscopy was observed to be less sensitive and specific (61.54%, 96.57% ) when
compared to Cartridge Based Nucleic Acid Amplification test for Mtb (82.69%, 98.29%)
in the same 227 patients. To be eligible, study participants must have checked the agree to
participate box in the Study Information and Participation Consent form. MDR-TB and
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drug-susceptible TB patients’ medical records were not accessed and the patients not
enrolled if the agree to participate box was not checked.
Main Study Procedure
Consent from the clinic head was obtained from each PMDT treatment center or
drug-susceptible TB treatment centers identified (Appendix A). Upon the approval of the
PMDT treatment center or TB treatment center administrator, the Study Information, and
Participation Consent that’s translated in Filipino language were offered to potential study
recruits. To ensure that potential respondent understands the study, I provided an
individual study orientation in which he/she can freely ask questions and was provided
ample time approximately 1 hour to make a decision. Alternatively, I facilitated a small
group study orientation to allow those who might want to participate to self-select, in
which they can freely ask questions and were provided ample time approximately 1 hour
to make a decision. When a recruit volunteered to be a study participant and has signed the
informed consent, I assigned a study identification number following a standardized
nomenclature to each study participant. The identification system start’s with the first
letters of the clinic name, followed by a patient number and Co for control or Ca for the
case as defined in the study. If the patient ID is, SLHP05Ca meant the respondents came
from San Lazaro Hospital, patient number five and was classified under the case group
having diagnosed to be infected with MDR-TB. A password protected Excel central
database was created with the identity of the respondents. The study identification number
was written on the questionnaire and the clinical record data extraction form. Each
questionnaire and the medical extraction form were placed inside an envelope. Then the
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questionnaire that is in the Filipino language was offered to each participant that signed
the Study Information and Participation Consent Form. The respondents answered the
questionnaire in an area designated by the facility. The respondents handed over the
envelope with the answered questionnaire to the researcher for review and storage. I
provided a list of the patient to the clinic/hospital and the envelope with the respondent's
clinical record extraction form. Clinic/Hospital was requested to review the patient clinical
record to verify whether the patient is either a laboratory confirmed MDR-TB or a
laboratory-confirmed Drug-Susceptible TB, and the most recent HIV test result (if
available) and was documented in the Respondents – Clinical Record Extraction Form
(Appendix B).
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Figure 7. Schematic diagram of the Main Study Procedure
Sample Size Selection
Given the need for the researcher to be personally present during interaction with
the study subjects, due to the geographical location of the Philippines and accessibility;
the I planned to administer the questionnaire to 50 MDR-TB patients and 50 drugsusceptible TB patients. However, to determine the ideal sample size, a priori power
analysis based on chi-square test of independence was conducted to determine the
minimum sample size required for this study using Gpower 3.1.9.2. Assuming a moderate
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effect size (Cohen’s w = 0.3) and a significance level of 0.05, the minimum sample size
required to detect a significant effect with 80% power is 108. Thus, 54 control subjects
among patients with drug-susceptible Tuberculosis, and 54 cases among patients with
clinically confirmed MDR-TB was the ideal sample size in this study.
Data Base Development and Analysis
The study assessed the strength of the association between the identified possible
risk factors and MDR-TB infection in the Philippines. Specifically, the study examined
whether the following independent variables are associated with MDR-TB infection: (a)
previous TB treatment; (b) infected with Human Immunodeficiency Virus; (c) exposure to
drug-susceptible TB/MDR-TB patient; (d) delayed diagnosis and treatment;
(e) employment status; (f) smoking; (g) imprisonment; (h) alcohol abuse and (i)
compliance with drug-susceptible TB treatment regimen.
This study attempted to answer the null hypothesis that the MDR-TB infection is
not associated with any of the following possible risk factors as determined by the
questionnaire: (a) previous TB treatment; (b) infection with Human Immunodeficiency
Virus; (c) exposure to drug-susceptible TB/MDR-TB; (d) delayed in diagnosis and
treatment; (e) employment status; (f) smoking; (g) imprisonment; (h) alcohol abuse and (i)
compliance with drug-susceptible TB treatment regimen. In addition the alternative
hypothesis in this study is: MDR-TB infection associated with one or more of the
following possible risk factors as determined by the standardized questionnaire: (a)
previous TB treatment; (b) infection with Human Immunodeficiency Virus; (c) exposure
to drug-susceptible TB/MDR-TB; (d) delayed in diagnosis and treatment; (e) employment
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status; (f) smoking; (g) imprisonment; (h) alcohol abuse and (i) compliance with drugsusceptible TB treatment regimen.
Quality Control of Data
To ensure quality control of data obtained through the following steps were strictly
followed:
1. Checked and reviewed the questionnaire that was translated into the Filipino
language before the study recruit leaves for missing, incomplete or inconsistency
of information data.
2. Consistency checked on each questionnaire to determine logic or compatibility of
the answer to related questions.
3. A questionnaire with incomplete information or inconsistent information was
returned before the study recruit leaves to clarify with the study respondents if the
question was understood.
4. Study respondents were not required to change the answer to the question if he/she
does not like to do so.
5. Each questionnaire was evaluated against the corresponding clinical record to
ensure the respondents satisfy the inclusion criteria.
Data was entered immediately in the database and validated. All completed questionnaire
was kept in a secured file.
Database Development and Management
The database was developed by the researcher that contains the independent
(possible risk factors) and dependent (outcome) variables under consideration in this
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study. Respondents in the database were identified through the pre-assigned study
identification number by the investigator. Questionnaire of study respondents with not
more than three missing data or inconsistent answer was used in the development of the
database. All questions on the questionnaires were pre-coded as shown in Table 2 to
facilitate database development and statistical analysis.
Quality control check of data entry was done at each stage of data entry through
verification and cross matching of the response entry of the respondents, linkage of study
participant study number to the entered data, correct classification of the respondents (i.e.
case or control) and hospital or clinic source of the respondents. All data entered was
reviewed and verified to ensure its accuracy before the start of the analysis.
Table 2
Measurement Level and Coding for Independent Variables
Information
Variable
Variable type
source

Previous TB treatment

B.10-12

Independent

Human immunodeficiency
virus infection

D.24-25

Independent

Measurement level and
coding
Categorical
1 = Isoniazid (INH)
2 = Ethambutol (EMB)
3 = Rifampicin (RIF)
4 = Pyrazinamide (PZA)
5 = Others
6 = Not answered
Categorical
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1 = yes
2 = No
3 = Not answered
Exposure to drugsusceptible TB/MDR-TB
patient

Categorical
A.1-4

Independent

1 = yes
2 = No
3 = Don’t Know
4 = Not answered

Delayed diagnosis and
treatment

Categorical
0 = 1 week or less
A.6-8

Employment status

5

Independent

Independent

1 = 2 weeks
2 = 3 Weeks
3 = A month
4 = Greater than 1 month
5 = I don’t remember
6 = No answer
Categorical
1 = Unemployed
2 = Employed
3 = Retired
4 = Not answered

Smoking

Imprisonment

F.31-35

E.27-28

Independent

Categorical

Independent

1 = Occasionally
2 = Daily
3 = Not answered
Categorical
1 = yes
2 = No
3 = Not answered
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G.36-38

Independent

Alcohol use

Compliance with drug
susceptible TB treatment
regimen

Categorical
1 = Occasional only
2 = Once a week
3 = Every day
4 = Not answered
Categorical

B.13-17

Independent

1 = yes
2 = No
3 = Not answered

Data Analysis
Statistical Package for the Social Sciences (SPSS) software (IBM Corporation,
2014) was utilized to facilitate statistical analysis. Description of cases and controls was
performed by comparing the study respondent’s socio-demographic and clinical risk
factors as shown in the table below.

Table 3
Case and Control group socio-demographic and clinical risk factors Comparative
All
DrugRisk Factors
Respondents
MDR-TB
Susceptible
N=
TB
a) Previous TB Treatment
Isoniazid (INH)
Ethambutol (EMB)
Rifampicin (RIF)
Pyrazinamide (PZA)
Others
Not answered

P value
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(b) Human Immunodeficiency
Virus Infection
Yes
No
Not answered
(c) Exposure to drugSusceptible
TB/MDR-TB patient
Yes
No
Don’t Know
Not answered
(d) Delayed diagnosis and
treatment
One week or less
Two weeks
3 Weeks
4 weeks
Greater than 1 month
I don’t remember
No answer
(e) Employment status
Unemployed
Employed
Retired
Not answered
(f) Smoking
Occasionally
Daily
Not answered
(g) Imprisonment
Yes
No
Not answered
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(h) Alcohol Use
Occasional only
Once a week
Every day
Not answered
(i) Compliance with drug
susceptible TB treatment
regimen
Yes
No
Not answered
Comparative Descriptive Analysis
Each of the categorical independent variables was tested to assess the statistical
significance of the association with the dependent variable through the application of the
chi-square test. A t-test was applied for the independent interval variable. The alpha level
was 0.05, such that when p< 0.05 it was considered indicative of a statistically significant
association with the dependent variable. To address the research question and determine
which of the hypothesis is acceptable, the independent variables or risk factors that have a
statistically significant association were further analyzed following the odds ratios.
Participants and Data Protection
Approval to conduct the research was obtained from the Walden University
Institutional Review Board. Ethical issues required by IRB were strictly observed in the
research process. The researcher does not have any personal biases relative to the study
that could jeopardize its scientific objectivity; or any conflicts of interest relevant to the
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research. To ensure confidentiality of participant’s data information the following steps
were followed:
1.

Participation in the study is voluntary in nature.

2.

Study respondents consent was obtained through an informed consent

process and signing of the Study Information and Participation Consent form
translated in the Filipino language.
3.

Study participants were only identified in the questionnaire through Study

ID Number.
4.

The master database in Excel format was not linked the Study Number to

the Name of the respondents and was secured through a password accessible only
by the researcher.
5.

Study records/files were stored in a secured manner for 5-yrs and then

destroyed.
6.

The data was presented only in aggregated form; no patient identifiers were

included in any reports of results.
7.

Written permission was obtained from appropriate authority to access the

data needed for the study.
8.

A two page summary of the study results was provided to each

hospital/clinic from where the study respondents were obtained which will be
posted in hospital/clinic public bulletin board. The Philippines Department of
Health and the World Health Organization’s Regional Office for the Western
Pacific (located in Manila, Philippines), and the Philippine Tuberculosis Society
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will also be provided with the two-page summary result. If invited to present the
study power point presentation will be utilized.
9.

I followed the rules required by the hospital/clinic administration during

the conduct of the research study.
The study commenced following the stated methodology of data collection and database
development, which was approved by the Walden University Institutional Review Board
(IRB).
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Chapter 4: Results
The analysis performed is presented in this chapter in order to find out if there is
an association between MDR-TB infection and the following possible risk factors:
previous TB treatment, infection with HIV, exposure to an unknown TB patient, delay in
TB diagnosis and treatment, employment status, smoking, imprisonment, alcohol abuse,
and/or compliance with the TB treatment regimen.
Chapter 4 will start with the comparative descriptive demographics for Cases and Control
patients. Univariate and bivariate analysis of possible risk factors are described in each
section.
Data Collection
Data used in the analyses were gathered from MDR-TB and drug-susceptible TB
infected respondents using a questionnaire (see Appendix C) that I developed. The
informed consent and questionnaire were translated into Filipino language or Tagalog by
the Department of Filipino and Philippine Literature of the College of Arts and Letters,
University of the Philippines (see Appendix D and E). Permission to conduct the research
(see Appendix F) was obtained from the Philippine government administered health center
through the Disease Prevention and Control Bureau of the Department of Health (DOH).
The study was approved since the research topic is consistent with the research agenda of
Philippines DOH’s TB program.
Study respondents for the Control group (drug-susceptible TB patients) were
recruited from health centers in the towns of Burauen, Tanauan, Capoocan, Barugo,
Dagami, and Carigara all located in the province of Leyte in Region VIII (Eastern
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Visayas). Approval from the person-in-charge at each health center or TB program was
obtained (see Appendix G, H, I, J, K, and L). For some of the MDR-TB patients, I secured
the town mayor’s consent was secured first because the Mayor's Office also administers
town health centers. I performed the administration of the questionnaire in November
2015.
Data for the cases were collected from the town of San Mateo’s Programmatic
Management of Drug-Resistant TB Health Center. The town is located in the province of
Rizal in Region IV-A. Approval from the person-in-charge at each health center or TB
program was obtained (see Appendix M). Most study participants within the Cases group
were voluntarily recruited from San Lazaro Hospital in March 2016. The San Lazaro
Hospital Ethics Review Board endorsed the study (see Appendix N).
The respondent’s identification system was applied so that critical information of
participants is not present in the questionnaire and in line with Walden University IRBapproved research protocol described in Chapter 3. Data were collected and entered into a
database. It was originally proposed that only questionnaires with fewer than three
unanswered items would be considered in the database development. However, this would
only provide 35 respondents for Control and 43 for Cases, which would not meet the
minimum of 54 respondents for each group. To avoid selection bias all the 172
respondents (Control = 93 and Cases = 79) were included in the database development.
Inclusion of the entire respondents in the data base development provides a better
understanding and documented justification as to the weakness of the study. In addition,
such process provided the foundation for improvements and modifications that will be
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stated in the recommendation section of the study in case a similar study is conducted in
the future by another researcher. The statistical analyses were performed using statistics
described in chapter 3, with the aid of Statistical Package for the Social Sciences (SPSS)
software.
Descriptive Epidemiology
In this section, I summarize the demographic profiles of Cases and Controls
patients. Sociodemographic characteristics include age, gender, place of birth, education,
employment status, and source of income.
Distribution of Controls and Cases. A total of 172 TB patients were recruited.
The study population is not representative of all MDT-TB and drug-susceptible TB
patients in the country. The Controls group had 93 respondents who were recruited from
the different health centers and who voluntarily accepted to answer the study
questionnaire. In this group, 44.1% respondents were from the town of Burauen. This is
followed by lesser percentages from the towns of Dagami (16.1%), Carigara and
Capoocan (12.9%), Tanauan (7.5%), and Barugo (6.5%). The Cases group was composed
of 79 respondents. Most (88.6%) of the respondents came from the PMDT section of San
Lazaro Hospital, which was selected as a study site because it is one of the DOH hospitals
that has been designated to treat MDR-TB. The other respondents were from the health
clinics of San Mateo, Rizal (3.8%), Barugo and Dagami (2.5%), and Tanauan and
Capoocan (1.3%).
The Philippines, being an archipelago, is generally divided into the three large
islands of Luzon, Visayas, and Mindanao. Based on the last population census, which was
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conducted in August 2015, Luzon had a population of 57, 470, 097; Visayas, 19,373, 431;
and Mindanao, 24,135, 775 (Philippine Statistics Authority, 2015). Inquiry with the
Philippine National TB Control Program Management Office revealed that the MDR-TB
risk factors that were considered in this study are not obtained as part of data collection on
the subnational incidence rate of TB.
The health centers from which Control respondents were recruited are located in
the province of Leyte, which is part of the Eastern Visayas region of the Philippines. Most
of the respondents in Controls reside in the province of Leyte, 80.1%. Among these
respondents, 14.9% were born in Mindanao 4.6% in Luzon. All 79 members of the Cases
group answered the question regarding place of birth; 87 of the 93 members of the Control
group did so. However, 64.6% of respondents in Cases were born in Luzon, which is
where San Lazaro Hospital is located. Some respondents from Cases were born in
Mindanao (5.1 %) and Visayas (30.4%). A chi-square test showed a statistically
significant difference (p < 0.0001) between Cases and Controls regarding place of birth.
Gender. There were 104 male and 68 female respondents. There were 33 (35%)
females and 60 (65%) males in the Controls, group and 35 (44%) females and 44 (56%)
males in the Cases group. More male respondents was recruited for Controls (60) as
compared to Cases (44). There is only a difference of two female respondents between the
two study groups. A chi-square test showed that there is no significant difference (p
>0.05) between gender distribution or gender profile of the Control and Cases.
Educational Attainment. Comparison of the Cases and Controls respondents
educational attainment showed a difference between the two groups. The Cases are
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generally more educated having more respondents completed high school and college
education. The prevailing educational attainment of the respondents from the Control
group is elementary education. The difference in the education profile between Cases and
Controls is statistically significant when the Bonferrono correction was applied (p =
0.006) at two levels of education attainment which are elementary and high school.
Table 4
Educational Attainment for Controls and Cases
Controls (n = 93)
Educational Attainment
Frequency Percent

Cases (n = 79)
Frequency Percent

Chi
square

p
value

None

6

6.5

2

2.5

1.48

0.22

Elementary

70

75.3

33

41.8

19.95

0.00

High School
0
0
20
25.3
26.64
0.00
a
College and Masters
17
18.3
24
30.4
3.44
0.06
2
Note: Pearson Chi-Square, X = 36.567
Degree of freedom = 7
Bonferroni's adjustment p < 0.006
a
In the Cases the data for College & Masters were aggregated for this analysis since
only 1respondent has a Master’s Degree and 0 from Controls.
Table 4 showed that most respondents in the Control group had completed
elementary education (75.3%), followed by college degree (18.3%), some did not
complete elementary education (6.5%). Out of the 79 respondents with MDR-TB infection
2.5% did not complete elementary education which is generally provided free by the
Philippine government. Most of the respondents in the Cases completed elementary
education (41.8%) followed by college and master’s degree (30.4%). The respondents in
the Cases group that completed high school education is 25.3%, and those that did not
complete the free elementary education is 2.5%.
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Age Profile. Table 5 and Figure 8, show that in the Control group the respondent’s
age, ranged from 18 to 89 years old (Mean = 50.8, Std. Dev = 17.4). The male
respondent’s minimum and maximum age are 18 and 80 years old respectively with a
Mean of 49.7 and Standard Deviation of 16.2. The female respondent’s minimum and
maximum age are 19 and 86 respectively, with a Mean of 52.9 and Standard Deviation of
19.3. The t- test showed that there is no statistical difference (p = value 0.25, t = 0.8373, df
= 91) among the female and male respondents age in the Control group.
The male respondents in the Cases had a minimum and maximum ages of 18 and
71 respectively, with a Mean of 43.1 and Standard Deviation of 13.6. However, among
the females, 19 and 63 are the minimum and maximum ages respectively. The Mean age is
35.7 with a Standard Deviation of 12.8. Statistical analysis showed that there is a
difference (p = value 0.02, t = 2.4602, df = 77) among the female and male respondents in
the Case group with females statistically significantly younger than the males.
It was observed that MDR-TB respondents are of younger age compared to Drug
Susceptible TB (Table 5 and Figure 8). The Cases are younger with a Mean age of 39.8
while the Control is 50.8 (t-test, p<0.001).
Table 5
Age Distribution of Controls and Cases
Controls ( n = 93)
Age
Group
Cumulative
Percent
(years)
Percent
18-23
7.5
7.5
24-29
5.4
12.9
30-35
9.7
22.6

Cases (n = 79)
Percent
13.9
13.9
16.5

Cumulative
Percent
13.9
27.8
44.3
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36-41
42-47
48-53
54-59
60-65
66-71
72-77
78-83

9.7
11.8
10.8
10.8
12.9
7.5
7.5
5.4

32.3
44.1
54.8
65.6
78.5
86
93.5
98.9

84-89

1.1

100

11.4
13.9
12.7
10.1
3.8
3.8

55.7
69.6
82.3
92.4
96.2
100

Mean:
Std. Dev:
Mean:
Std. Dev:
50.8
17.3
39.8
13.7
Note: t test = 4.5817
95% CI of 6.29 - 15.81
p-value = < 0.001
Statistically significant difference in the age profile of the Controls and Cases.
Summary

Figure 8. Age of Cases and Controls
Note: Drug Susceptible TB Mean Age = 50.8
Std. Dev. = 17.3
MDR-TB Mean Age = 39.8
Std. Dev. = 13.7
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Employment Status and Sources of Livelihood. High unemployment was
observed in both Cases and Controls, most of the 93 Controls reported being unemployed
and retired (79.6%) and only 18.3% employed (Table 6). However, in the Cases the
unemployed and retired is 82.3% with the employed 17.7%. Two Controls did not disclose
their employment status. There is no statistically significant difference in employment
status between the Control and Cases (p > 0.88). Two respondents that did not indicate
their employment status were not included in the analysis.
Table 6
Employment Status of Controls and Cases
Controls (n = 93)
Cases (n = 79)
Employment Status
Frequency Percentage Frequency Percentage
Unemployed and Retireda
Employed
No Answer
Note: t test = 0.1581
95% CI of -77.28-86.61
p-value = >0.88
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79.6

65

82.3

17
2

18.3
2.2

14
0

17.7
0

Data analysis showed only 17 Control and 14 Cases (18.0% of 172 study
subjects overall who provided employment information -- see Table 7) had full time
source of livelihood. The primary reasons for unemployment among Controls are
health condition and unavailability of employment opportunities in the area.
Only 31 study subjects provided employment income information (14 Cases and
17 Controls). Most of the employed Cases (35.7%) as shown in Table 7 work for various
jobs (i.e. furniture working, laborer, a pedicab driver, campaign staff, electrician, sales
lady, taxi driver and vendor) as source of livelihood. However, one Case did not disclose
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the source of livelihood. Fishing/Farming is the predominant source of livelihood among
the employed Controls (52.9%) while Driver (28.6%) and Employment Income (28.6)
were most common among the Cases. The probable reason Fishing/Farming is the
predominant source of livelihood among the respondents in the Controls, is that the towns
in Leyte where the respondents were recruited are either coastal or agricultural area.
Driver and Employment income is the predominant livelihood of the Cases because the
majority of the respondents were from San Lazaro Hospital. The hospital is located in
Manila, a highly populated urban area, and the capital city. Thus this employment profile
is consistent with that setting.
Table 7
Controls and Cases that Provided Employment Information
Control (n = 17)
Cases ( n= 14)
Sources of Livelihood
Frequency Percent
Frequency Percent
Business/Employment
2
11.8
4
28.6
Income
Fishing/Farming
9
52.9
1
7.1
4
28.6
Driver
0
0
Others
6
35.3
5
35.7
2
Note: Pearson Chi-Square, X = 11.460
Degree of freedom = 7
p-value = 0.12
Others include: Furniture Making, Laborer, Painter, Pedicab Driver, Campaign
Staff, Electrician, Sales Lady, Taxi Driver, and Vendor
The result of the Pearson Chi-Square test indicates there is no statistically
significant difference between the ages of the respondents in the Controls and Cases
relative to their employment status (Table 8). Among the Controls, only 17 respondents
are employed; five were between ages 48 to 53. This could be attributed to their health
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conditions and unavailability of job opportunity in the area where the Control respondents
reside. The data in Table 8 revealed that of the total 14 respondents who are employed in
the Case group; six were between ages 18-35. This could be attributed as well to their
health conditions and unavailability of job opportunity in the area where the Cases
respondents reside.
To compare the age of controls and cases in relation to employment status, raw
data for age was utilized to perform the t test. The t test results indicated the following
conclusions: the mean age of employed and unemployed respondents is not statistically
different from both Controls and Cases, and the mean age of Cases is lower than the mean
age of Controls for both employed and unemployed.
Table 8
Comparative Age Group Distribution Between Controls and Cases in Relation to
Employment Status
Controlsa,c
Casesb,d
Age
Unemployede
Employedf
Unemployede
Employedf
(years)
(n = 72)
(n = 17)
(n = 60)
(n = 14)
18-23
24-29
30-35
36-41
42-47
48-53
54-59
60-65
66-71
72-77

7
5
8
7
10
4
8
8
6
5

0
0
1
2
1
5
2
3
1
1

10
8
10
7
6
8
8
2
1

1
3
2
2
4
1
0
0
1
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78-83

4

1

Mean Age
48.8
55.4
38.9
St.Dev Age
17.8
12.7
13.5
Note:
a
Relationship of Age to Employment status of Controls
Pearson Chi-Square, X2 = 12.326
Degree of freedom = 10
p - value= 0.26
b
Relationship of Age to Employment status of Cases
Pearson Chi-Square, X2 = 0.99
Degree of freedom = 8
p - value = 0.42
c
Comparison of Age between Unemployed and Employed Controls
t = 1.43
df = 87
CI= -15.68 to 2.56
p - value = 0.16
d
Comparison of Age between Unemployed and Employed Cases
t = 0.007
df = 72
CI= - 7.93 to 7.88
p - value= 0.99
e
Comparison of Age between Unemployed Cases and Controls
t = 3.622
df = 130
CI= 4.35 to 15.43
p - value = 0.001
f
Comparison of Age between Employed Cases and Controls
t = 3.579
df = 29
CI= 7.04 to 25.81
p - value= 0.001

38.9
12.7

Hypothesis Testing
The research question in the study is to find out if there is an association between
MDR-TB infection and the following possible risk factors: Previous TB Treatment,
Infected with Human Immunodeficiency Virus, exposure to drug-susceptible TB/MDR-
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TB patient, delayed in diagnosis and treatment, employment status, smoking,
imprisonment, alcohol abuse, and compliance with TB treatment regimen.
The null hypothesis (H0) and alternative hypothesis (H1) were formulated to
objectively identify which of these possible risk factors are associated with MDR-TB
infection. The 0.05 alpha or pre-set level of statistical significance was used to which all
the p-values were compared to determine whether or not to reject the null hypothesis.
Analysis of probable risk factors for Multi-Drug Resistant TB infection was done
consistent with the Case-Control design. The Cases are respondents with MDR-TB and
Controls are the respondents with Drug Susceptible TB. Comparison of these risk factors
was made between Cases and Controls.
Table 9 shows the results of the assessment whether there is an association of the
pre-identified potential risk factors in this study to MDR-TB infection. Chi Square test
was used for risk factors with large cell sizes, i.e. Previous TB treatment, Delayed
Diagnosis, Exposure to Drug Susceptible TB/MDR-TB patient, Smoking, Compliance
with drug susceptible TB treatment regimen and Employment Status. Fisher exact test was
used for risk factors with small cell sizes or whose expected values are less than 5, i.e.
HIV, Imprisonment and Alcohol Use. Though it is desirable not to have missing data;
missing data are almost present in all quantitative studies (Dong and Peng 2013, Zhu,
Ibrahim and Tang 2014). The most prevalent reason for incomplete data is item nonresponse. This would mean that incomplete information collected from a respondent in
which case in this study was; refusal of the respondent to provide information in the
questionnaire due to personal reasons, which was respected by the researcher. In this study
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missing data was handled following list wise deletion (where the study subject's record
was excluded from analysis if an essential data element was missing). This means that
complete analysis was performed on answered risk factor while excluding those that were
not answered. This approach of dealing with missing data reduced the sample size
available for analysis, but provided an unbiased parameter estimate (Dong and Peng,
2013).
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Table 9
Candidate Risk Factors p value Between Cases and Controls
P value
Risk Factors
a) Previous TB Treatment

All Respondents

MDR-TB

Drug Susceptible TB

N = 62

n = 26

n = 36

5 (8.06)

2 (7.69)

3 (8.33)

Chi-Square
Test

Fisher Exact Test

Isoniazid (INH) +
Ethambutol

0.3

(EMB)- Baseline
Rifampicin (RIF)

47 (75.81)

22 (84.64)

25 (69.44)

Pyrazinamide (PZA)

10 (16.13)

2 (7.69)

8 (22.22)

(b) Human Immunodeficiency Virus
infection

N = 120

n = 73

n = 47

Yes

4 (3.33)

4 (5.48)

0 (0.00)

No

116 (96.67)

69 (94.52)

47 (100.00)

(c) Exposure to drug-susceptible TB/MDRTB Patient
Yes

N = 102

n = 42

n = 60

52 (50.98)

26 (61.9)

26 (43.33)

50 (49.02)

16 (38.1)

34 (56.67)

(d) Delayed diagnosis and treatment

N = 109

n = 44

n = 65

One week or less - Baseline

26 (23.85)

11 (25.00)

15 (23.08)

Two weeks

27 (24.77)

12 (27.27)

15 (23.08)

3 - 4 Weeks

17 (15.60)

7 (15.91)

10 (15.38)

Greater than 1 month

39 (35.78)

14 (31.82)

25 (38.46)

No

0.15

0.33

0.91
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(e) Smoking
Occasionally

14 (21.21)

4 (11.43)

10 (32.26)

Daily

52 (78.79)

31 (88.57)

21 (67.74)

0.04*

Continuation Table 9
(f) Imprisonment h

N = 153

n = 66

n = 87

Yes

10 (6.54)

5 (7.58)

5 (5.75)

No

143 (93.46)

61 (92.42)

82 (94.25)

(g) Compliance with drug susceptible
TB treatment regimen

N = 127

n = 70

n = 57

Yes

107 (84.25)

52 (74.29)

55 (96.49)

No

20 (15.75)

18 (25.71)

2 (3.51)

N = 102
94 (92.16)
8 (7.84)

n = 42
37 (88.1)
5 (11.90)

n = 60
57 (95.0)
3 (5.00)

N = 170

n = 79

n = 91

Unemployed + Retired

139 (81.76)

65 (82.28)

74 (81.32)

Employed

31 (18.24)

14 (17.72)

(h) Alcohol Use
Occasional Only + Once a week
Everyday
(i) Employment Status

0.75

17

0.001*

0.27

0.87

(18.68)

Notes:
* Statistically significant, p – value < 0.05.
1respondent from Controls and 0 from Cases that answered; others were excluded from the Chi Square test calculation.
b
Multiple responses (42 from Cases and 0 from Controls) were not included in the calculation. 67 respondents did not answer
the question on previous TB treatment.
c
52 respondents did not answer the question on HIV testing.
d
70 respondents did not answer the question on exposure to Drug-susceptible TB/MDR-TB patient.
e
The “Don’t remember response” excluded 9 (Cases) and 10 (Controls) from the Chi Square test calculation. 44 respondents did
a
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not answer the question of delayed diagnosis and treatment.
Combined the 3weeks and 4 weeks in the calculation for Chi Square, since no (0) respondent from Control was delayed in
diagnosis and treatment for 3 weeks.
g
106 respondents did not answer the question on smoking.
h
19 respondents did not answer the question on imprisonment.
i
45 respondents did not answer the question on Compliance with drug susceptible TB treatment regimen.
j
70 respondents did not answer the question on alcohol use.
k
2 respondents from Controls did not provide employment status information.
f
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The Chi-Square test results as shown in Table 9 revealed that previous TB
treatment with p-value of 0.30 is not a significant risk factor for MDR-TB infection. The
68 respondents that did not answer on previous TB treatment question were not included
in the calculation. The 42 Cases with multiple responses to the question (previous TB
treatment) and 0 from Controls is consistent with the Cases having been previously
treated for Drug susceptible TB. Multiple responses were also not included in the analysis
since this is only selected by Cases and not by Controls. TB treatment in the Philippines
is provided by the Department of Health free of charge through the various town health
centers and government hospitals. The drug treatment formulation could be fixed-dose
combination (HR-Isoniazid and Rifampicin, HRE-Isonizid, Rifampicin and Ethmbutol,
HRZE- Isonizid, Rifampicin, Pyrazinamide and Ethmbutol ) or single drug formulation
which could be either as tablet, syrup or injectable (Streptomycin) form (Philippine
Department of Health- Manual of Procedures for the National TB Control Program,
2013).
HIV as a risk factor for MDR-TB infection is shown not to be statistically
significant (p = 0.15). The 52 respondents that did not indicate in the questionnaire if they
have been tested for HIV were not included in the calculation. Data showed that in the
study population, 4 from Cases were found to be HIV positive compared to 69 which are
HIV negative. The HIV data was confirmed by the healthcare provider through the
Clinical Record Extraction Form designed for this study. The 52 respondents that did not
indicate if they have been tested for HIV were confirmed by the health care provider.
HIV testing for TB patient is generally not required in the Philippines. To be tested for
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HIV the TB patient should be 15 years old and above and either live in pre-identified
high priority for HIV or belong to a high-risk clinical groups. This policy is anchored on
the fact that laboratory testing services are centralized in urban areas, inadequate logistics
and death rate is not high in TB-HIV target areas (Philippines Department of HealthNational TB Control Program, 2014). Refer to page 85 for further discussion of this
issue.
Exposure to Drug-susceptible TB/MDR-TB patient as a risk factor for MDR-TB
infection is shown in Table 9 as not statistically significant (p - value = 0.33). Survey
showed that in Cases, the exposure to Drug-susceptible TB/MDR-TB infected person was
described by Cases as being from friends with once in a while contact (7), house mate
with every month contact (14), house mate with once in a month contact (3) and work
place with once in a while contact (2). Among Controls, exposure to Drug-susceptible
TB/MDR-TB patient was described by Controls as being from: house mate with every
month contact (4) and with once in while contact (10), friend with once in while contact
(5), work place with once in a while contact (4), cockfighting arena with once in a while
contact (1), store with once in a while contact (1), and 1 respondent did provide the
source and frequency of contact to the person with TB that might have cause the
respondent to get infected with the disease. As shown in Table 10, a total of 52
respondents answered yes to the TB/MDR-TB contact or exposure question while 50
respondents answered no. However out of the 172 respondents in the study, 70
respondents did not answer the questions on Exposure to Drug-susceptible TB/MDR-TB
patient; making it susceptible to possible bias. Delayed diagnosis and treatment as a risk
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factor for MDR-TB infection as shown in Table 9 is not statistically significant (p =
0.91). It was observed that most of the respondents (35.78%) sought medical diagnosis
and treatment after more than a month of experiencing the signs and symptoms of TB.
This finding is reflective of the Department of Health -National TB Control Program,
updated 2010-2016 Philippine Plan of Action to Control Tuberculosis wherein it states
that the TB smear-positivity rate is only 15% nationally, with a wide variance of over
30% from the test results provided by the various Local Government Unit Health Centers.
The report attributed the low national TB smear-positivity rate due to lack of TB
symptoms awareness, unwillingness to provide sputum for M. tuberculosis diagnosis, and
most likely case findings, in general, is not yet as rigorous compared to other countries
because of resource limitation. The Philippines TB smear-positivity rate is lower
compared to a smear positivity meta –analysis study done among pediatric and adult TB
patient wherein pediatric TB cases, the TB smear-positivity rate of 6.8% and 52.0%
among adult TB cases in 14 countries (Kunkel et al., 2016). One potential reason cited
why the smear-positivity rate is low in the Philippines was that the standardized staining
protocols are not available at the peripheral level resulting in variable practices that
impact on overall smear quality and results in addition to the not fully functional quality
assurance system for smear microscopy (Philippines Department of Health -National TB
Control Program, 2014). The key to TB control is early detection before it progresses into
the contiguous state. One of the limitations of the direct smear using the sputum was that
it could not detect the presence of paucibacillary TB. The presence of paucibacillary
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bacteria is below the detection limit in direct smear test, this lead into a smear-negative
result among pediatric, extra pulmonary tuberculosis (Restrepo; et.al, 2006).
Among the 44 Cases who answered the question (if they seek immediate medical
help upon experiencing TB infection symptoms) only 8 indicated the reasons while 36
did not answer the question. The reasons respondents provided for not immediately
seeking medical attention are: no money for transportation (1), ashamed of the infection
(1), works (2), No budget or money (4). A total of 65 Controls answered the question.
However only 8 indicated the reasons why they did not seek immediate medical help.
The reasons given were: did not mind the symptoms (1), don’t know of TB symptoms
(1), forgetfulness (1), financial (2), no money for transportation (1), going to die anyway
(1), and don’t know that coughing is one of the TB infection symptoms (1).
Smoking was found to be associated with MDR-TB infection as shown in Table 9
(p = 0.04). Data indicated that the null hypothesis which is smoking is not a risk factor
for MDR-TB infection is rejected. However, Bonferroni correction was not performed
because there is no risk of type 1 error (rejecting the null when the null is, in fact, true)
since there were only two categories of comparison on the frequency of smoking which is
occasionally and daily (Lesack and Naughler, 2011).
The total study population that reported being a smoker before TB infection was
66. Some respondents smoke daily (52 respondents), while some on an occasional basis
(14 respondents). Data showed that out of the 93 Cases, and 79 Controls in the study
population, 58 and 48 respectively did not answer the question if they are smoking before
infected with TB.
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A total of 10 respondents in the study population reported having been imprisoned
while 143 did not experience imprisonment. The SPSS results for imprisonment (Table
9) as a potential risk factor candidate for MDR-TB infection, showed that it is statistically
not significant (p = 0.75).
Compliance with drug susceptible TB treatment regimen as a risk factor is
associated with MDR-TB infection (p = 0.001). Data indicated that the null hypothesis
which is compliance with drug susceptible TB treatment regimen is not a risk factor for
MDR-TB infection is rejected. However, Bonferroni correction was not performed
because there is no risk of type 1 error (rejecting the null when the null is, in fac,t true)
since there were only two categories of comparison which are yes and no (Lesack and
Naughler, 2011). A total of 107 respondents both from Cases (52) and Controls (55)
reported complying with the TB treatment regimen which is administered through the
DOT (Directly Observed Therapy). It was observed that out of the 172 total study
respondents, 45 (9 Cases, 36 Controls) did not answer on compliance with TB treatment
regimen. However, 18 MDR-TB respondents did not previously follow the drug
susceptible TB treatment regimen for various reasons. Five did not indicate the reasons
for not following the TB treatment regimen while 13 gave the following reasons: work
schedule (1), financial (1), drug side effect (1), feel lazy (2), shy for people to know about
the infection(1) , was told by the doctor to stop for a reason that the respondent don’t
remember (1), health care provider not strict(1), vomited blood after 5 months(1), no
money (1), no more coughing(1), still feel ok (1) and feels ok after taking some of the
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treatment (1). Thought TB infection is gone and cannot sleep were the reasons cited by
two Control respondents for not complying with the treatment regimen.
The Fisher Exact test result for alcohol use (p = 0.27) and Chi-square test result
for employment status (p = 0.87) (Table 9) as a potential risk factor candidate for MDRTB infection showed not statistically significant. Data showed that more respondents
from Controls (43) drink alcohol occasionally than the Cases (27). More respondent in
the study population (139) are either unemployed or retired when compared to those who
are employed (31).
This study aimed to determine if the identified risk factors were associated with
MDR-TB infection. The association was measured using Odds Ratio (OR) in which the
precision is estimated by the value of the 95% Confidence Interval (CI). Thus if the OR
between Cases and Controls groups is 1, this indicated that there was no difference
between the two groups relative to the risk factors under consideration. However, if the
OR is > 1, this indicates that the risk factor under consideration affects an increase in
Cases rather than Control, and vice versa if the OR is < 1. If the CI is narrow, OR is
more precise when compared to a CI value that is broader (Szumilas, 2010).
A validation of the Chi Square statistical results was performed using the Odds
Ratio (Table 10) which is the ideal statistical test for Case Control design. Results
showed that the OR values and Chi-Square test results are consistent with each other, that
is, possible risk factors deemed significant based on the Chi Square test have OR 95% CI
which do not contain 1.
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Table 10
Candidate Risk Factors Odd Ratio to MDR-TB Infection
Risk Factors
a) Previous TB Treatment a
Isoniazid (INH) + Ethambutol (EMB) – Baseline
Rifampicin (RIF)
Pyrazinamide (PZA)

95% CI

Odds Ratio

Lower

Upper

1.32
0.375

0.202
0.035

8.639
3.999

0

0

0

0.471

0.21

1.053

1.091
0.955
0.764

0.368
0.276
0.276

3.235
3.299
2.11

3.69*

1.021

13.341

0.744

0.206

2.684

9.519*

2.104

43.059

2.568

0.579

11.392

(b) Human Immunodeficiency Virus infection
Yes – Baseline
No
(c) Exposure to drug-susceptible TB/MDR-TB Patient
Yes – Baseline
No
(d) Delayed diagnosis and treatment b
One week or less - Baseline
Two weeks
3 - 4 Weeks c
Greater than 1 month
(e) Smoking d
Occasionally – Baseline
Daily
(f) Imprisonment
Yes – Baseline
No
(g) Compliance with drug susceptible TB treatment
Regimene
Yes – Baseline
No
(h) Alcohol Use
Occasional Only + Once a Week – Baseline
Everyday
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Continuation Table 10
(i) Employment Status
Unemployed + Retired – Baseline
Employed

0.938

0.429

2.049

Notes: * Significant in Chi-Square p value < 0.05
a
1 respondent from Controls and 0 from Cases that answered Other was excluded
from the Odds Ratio calculation.
b
The Don’t remember response 9 (Cases) and 10 (Controls) were excluded from
the Odds Ratio calculation.
c
Combined the 3weeks and 4 weeks in the Odds Ratio, since no (0) respondent
from Control was delayed in diagnosis and treatment for 3 weeks.
d
Drug Susceptible TB patients who are daily smokers is 3.69 x more likely to
have MDR-TB infection than occasional smokers. The OR is statistically greater
than 1 because the 95% CI does not contain 1.
e
Drug Susceptible TB patient who does not comply with the treatment regimen is
9.519 x more likely to have MDR-TB infection than those who comply with the
Drug Susceptible TB Treatment Regimen. The OR is statistically greater than 1
because the 95% CI does not contain 1.

Based on the Chi-Square test in Table 9, the 2 significant risk factors for MDRTB infection were: Smoking (p - value = 0.04) and Compliance with drug susceptible TB
treatment regimen (p - value = 0.001). The same two risk factors as shown in Table 10
have 95% confidence interval not containing 1, i.e. Smoking (1.021, 13.341) and
Compliance with drug susceptible TB treatment regimen (2.104, 43.059).Drug
susceptible TB patient who are daily smokers (OR 3.69) are three times more likely to
develop a MDR-TB infection than those who smoke occasionally. Additionally,
respondents who did not comply with or adhere to drug susceptible TB treatment regimen
(OR 9.519) are nine times more likely to develop a MDR-TB infection than those who
regularly follow the treatment for drug susceptible TB infection.
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Summary
This research attempted to answer the research questions (s) if there is association
between MDR-TB infection and the following possible risk factors: (a) previous TB
treatment, (b) infection with Human Immunodeficiency Virus, (c) exposure to TB patient,
(d) delayed TB diagnosis and treatment, (e) smoking, (f) imprisonment, (g) compliance
with the TB treatment regimen, (h) alcohol abuse, and (i) employment status. The data
presented in this chapter using Chi Square test was applied to risk factors with large cell
sizes, i.e. Previous TB treatment, Delayed Diagnosis, Exposure to Drug Susceptible
TB/MDR-TB patient, Smoking, Compliance with drug susceptible TB treatment regimen
and Employment Status. Further, Fisher exact test was used for risk factors with small
cell sizes or whose expected values are less than 5, i.e. HIV, Imprisonment and Alcohol
Use.
Given the data collected from the study, results showed that smoking and
compliance with drug susceptible TB treatment regimen are the potential risk factors
associated with MDR-TB infection. The data in this study indicated that drug susceptible
TB respondents who do not comply with anti TB treatment regimen are nine times more
likely to develop MDR-TB when compared to those who regularly follow the treatment
regimen. Further, it was also found out from the analysis of the data that drug susceptible
TB respondents who smoke on a daily basis is three times more likely to develop a MDRTB infection. It is reasonable that smoking is a risk factor for MDR-TB infection,
because one of the general adverse effects of smoking to the body includes inflammation
and which impairs immune function (Center for Disease Control and Prevention (2014).
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The ability to fight infectious disease such as MDR-TB of a person with impaired
immune system is compromised or entirely absent. Data in the study indicated that risk
factors such as previous TB treatment, infection with Human Immunodeficiency Virus,
exposure to TB patient, delayed TB diagnosis and treatment, imprisonment, alcohol
abuse, and employment status were not associated with MDR-TB infection. Discussions,
recommendations, potential social implications as well as the recommendations for
further research are discussed in Chapter 5.
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Chapter 5: Discussion, Conclusions, and Recommendations
Introduction
The purpose of this quantitative study was to find out if there is an association
between MDR-TB infection and the following possible risk factors: (a) previous TB
treatment, (b) infection with HIV, (c) exposure to a TB patient, (d) delayed TB diagnosis
and treatment, (e) smoking, (f) imprisonment, (g) compliance with the TB treatment
regimen,( h) alcohol abuse, and (i)employment status. The study was anchored in the
epidemiological theory of John Snow. He pioneered the epidemiological approach to
causal inference work with an emphasis on the evaluation of preventive, ameliorative,
and curative interventions (Fine et al., 2013). The theory provided an understanding of
the agent, the environment, and the host as a framework for the dynamics of disease
transmission.
A case-control design was followed, wherein MDR-TB respondents were
assigned to one group (Cases) and drug-susceptible TB respondents to another group
(Controls). Data were obtained using a self-administered survey questionnaire that I
designed for the study. The questionnaires included demographic information and risk
factors sections. Controls and Cases were selected based on the eligibility criteria
mentioned in Chapter 3. They voluntarily participated in the study.
Members of the Controls group were from towns of Burauen, Dagami, Carigara,
Capoocan, Tanuan and Baguro. The towns are located in the Visayas region of the
Philippines. The majority (88.6%) of the Cases were from the PMDT section of San
Lazaro Hospital, which is one of the hospitals designated by the Philippine Department of
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Health hospitals to treat MDR-TB patients. Some of the Cases respondents were recruited
from the health clinics of San Mateo, Rizal, Barugo and Dagami, and Tanauan and
Capoocan.
It was originally proposed that only questionnaires with less than three
unanswered items would be considered in the database development. However, because
of logistic problems in obtaining more respondents, potential selections bias, and to better
provide justification as to the weakness of the study, all answers from the 172 study
respondents (93 Controls and 79 Cases) were included in the analyses.
Statistical analysis using chi-square and Fisher Exact tests and Odd Ratio were
performed. Complete data analysis was performed concerning risk factors. The results of
the multiple regression analysis show that smoking and compliance with drug susceptible
anti TB treatment regimen were associated with MDR-TB infection. Drug susceptible TB
respondents who smoke daily are three times (OR 3.690) more likely to develop a MDRTB infection. Similarly, drug-susceptible TB respondents who do not comply with the
treatment regimen are nine times (OR 9.519) more likely to develop a MDR-TB
infection. Risk factors such as previous TB treatment, infection with HIV, exposure to
TB patient, delayed TB diagnosis and treatment, imprisonment, smoking, alcohol abuse,
and employment status were not associated with MDR-TB infection (see Table 10).
Interpretation of the Findings
Data in this study suggest that the type of anti TB drug that the respondents had been
previously taking is not a significant risk factor (p = 0.30) for MDR-TB infection.
Conversely, as discussed in Chapter 4, Mtb drug resistance to anti-TB medicine was
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identified among patients with relapse treatment to Streptomycin in 1944 (Keshavjee &
Farmer 2012). The drug resistance was attributed to the disruption of the drug mechanism
target for bacterial protein synthesis (Goldberg, Siliciano, & Jacobs, 2012). WHO in 1994
initiated the Global Project on Anti-Tuberculosis Drug Resistance Surveillance to track
the prevalence of Streptomycin resistance. Project developers systematically collected
and analyzed data from 114 countries that reported first-line anti-TB drug resistance
(WHO, 2009). WHO data showed that the highest level of anti-TB drug resistance is in
Europe (WHO, 2010)
From the biological mechanism aspect, one has to consider the ability of the
organism to develop mutation or evolution, if the TB patient is taking substandard,
falsified anti-tuberculosis drugs, and failure to follow the prescribed treatment regimen.
The presence of substandard, falsified first line anti-tuberculosis drugs such as isoniazid
and rifampicin is present in Africa (10.1%), India (10.1%) and other middle-income
countries (3.9%; Bate et.al, 2013). The Philippines Food and Drug Administration
detected in 2012 a substandard first line anti TB drug that was part of the fixed dose
combination procured from a local manufacturer (Philippine Department of Health National TB Control Program, 2014).
To avoid possible mutation or evolution of the Mtb organism into a drug-resistant
strain, Zhao et. al. (2012) and Chen et al. (2013) underscored the importance of a highquality standard antibiotic treatment and a strict follow-up to ensure adherence by
patients to the prescribed regimen. Though DOTS is implemented in the Philippines, the
Joint Program Review observed that in some areas of the country irregular treatment
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increased the risk of drug resistenace (Philippine Department of Health -National TB
Control Program, 2014).
The 172 respondents in this study, only 104 and 68 respondents answered and did
not answered respectively, the question on previous TB treatment,which may have biased
the study findings. The Chi-square test showed that there is no statistical significance
difference (p = 0.89) between the Cases and Controls of the respondents that answer the
question in relation to previous TB treatment. The researcher expected the respondents
from the Controls to select no as an answer in the questionnaire especially for first time
diagnosed with Drug Susceptible TB. However, some respondents refused to answer the
questions despite the explanation provided by the researcher during the review of the
questionnaire. As a matter of ethical consideration refusal of the respondents to provide
an answer to an item in the questionnaire was profoundly respected by the researcher.
The aforementioned finding is not similar to the studies performed by Daniela and
Osmand (2011), and Skrahina et. al., (2013), wherein previous TB treatment is a risk
factor for MDR-TB infection in a study done in South West Nigeria and Belarus
respectively.
An immunocompromised patient such as those with HIV is highly susceptible to
TB infection which results in TB being a common comorbidity of HIV infection. To
better manage coinfection, WHO requires that key populations have the same access to
tuberculosis (TB) prevention, screening and treatment services as other populations at
risk of or living with HIV (WHO, 2016). In the Philippines HIV testing among TB
patient is required among patient above 15 years old, living in pre-identified priority
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areas and belong to high risk group (Philippines Department of Health-National TB
Control Program, 2014). The aforementioned PDOH policy is not aligned with the WHO
guidelines regarding routine HIV testing of all persons diagnosed with TB, and testing all
HIV-infected persons for evidence of Mtb infection. In this study,out of 172 respondents
only 120 provided HIV statsus and it was found that HIV infection was not associated
with MDR-TB infection. This could be attributed to the fact that most of the Control
respondents were from the different towns of Leyte (Eastern Visayas) which is not listed
as one of the Philippines Department of Health (PDOH) HIV testing priority areas. The
respondents in the Cases reside from the different parts of Metropolitan Manila which are
a PDOH priority area for HIV testing besides being infected with MDR-TB (a high
priority itself). The Updated 2010-2016 Philippine Plan of Action to Control
Tuberculosis recommended strengthening the HIV diagnosis among TB patient even if
the death rate is not high in TB-HIV target areas (Philippine Department of Health National TB Control Program, 2014). HIV testing among TB patient is not a requirement
for all TB patients. This is consistent with the WHO Western Pacific Region data (Figure
9); wherein in 2014 out of 250,000 newly registered TB cases only 50,000 were tested for
HIV despite being one of the fastest-growing HIV epidemics in the world (World Health
Organization Western Pacific Region, Philippines– Country profiles on HIV/AIDS,
n.d.b)
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Figure 9. HIV Testing Among Newly Registered TB Patient in the Philippines in 2013
and 2014. Adopted from: World Health Organization Western Pacific Region,
Philippines– Country profiles on HIV/AIDS (n.d.b).
The general mode of MDR-TB and Drug Susceptible TB transmission is through
inhalation of the Mtb tubercle bacilli that is present in the microscopic droplets from an
active TB infected person’s which are expulsed by coughing, sneezing, speaking, singing,
or laughing (Versaalovic et al., 2011;National Institute of Allergy and Infectious
Diseases,2010). Analysis of the data obtained from this study, found that self-reported
exposure to drug-susceptible TB/MDR-TB patient was not a risk factor for MDR-TB
infection (p = 0.07); however out of the 172 respondents, only 102 answered the question
on exposure to drug-susceptible TB/MDR-TB patient. Results of the Chi-square test
revealed no statistical difference (p = 0.95) between those respondents in the Cases and
Controls that provided answers to the questions relative to exposure to drug-susceptible
TB/MDR-TB patient. Conversely, following the scientific evidence of TB diseases
transmission, it is clear that exposure to drug-susceptible TB/MDR-TB is a risk factor.
This was found out in a study conducted in Kazakhstan where most study respondents
with MDR-TB infection had previous contact with the patient with drug-susceptible TB
or MDR-TB (Terlikbayeva et al., 2012).
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In the Philippines diagnosis and treatment of TB is provided free by the
government through various government hospitals and municipal health centers. It was
found out in this study that though delayed diagnosis and treatment (from the onset of TB
symptoms) is not associated with MDR-TB infection; 38.78% of the respondents sought
medical help after more than one month of experiencing the signs and symptoms of the
disease. The primary reason patients shared is financial constraint for one has to spend
for the transportation in going to health centers. Most of the study respondents from the
Controls reside in far flung areas of the town where the Municipal Health care provider is
stationed. Going to the clinic requires a tremendous task of sacrifice especially if the area
(Barrio) that the patient live does not have an accessible road. Some patients told the
researcher that they would rather spend their money to buy rice (a basic staple food in the
Philippines) rather than to pay for the transportation for in this manner more family
member will benefit. Delay to a timely care seeking was attributed to stigma to the
diseases, lack of proximity to health centers and treatment partners and the perceived
high cost of TB treatment (Philippine Department of Health -National TB Control
Program, 2014).
The predisposition of an infectious communicable disease should not only be
evaluated and assessed from a biological perspective but equally important is from the
various socio cultural, economic, behavioral factors that may have triggered an increase
in disease susceptibility (Berkman, L. F. & Kawachi, I., 2005). Smoking, imprisonment,
compliance with drug susceptible TB treatment regimen, alcohol use, and employment
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status were among the various socio cultural, economic, behavioral factors considered in
this study.
Smoking harms nearly every organ of the body thereby diminished the overall
health condition of the person (Butov et al, 2015). In this study, smoking was associated
with MDR-TB infection (p = 0.04). The researcher noted a low turnout response,
wherein only 65 out of 172 respondents provided an answer to the smoking questions.
The Chi-square test showed no statistical difference (p = 0.45) between those respondents
in the Cases and Controls that provided an answer to the question relative to smoking. It
can also be inferred from the data in the study that smoking is a generic risk factor for
lung disease (i.e. Drug Susceptible TB, MDR-TB). The association of smoking as a risk
factor to lung disease is scientifically explained in a study performed in Kharkiv region of
Ukraine by Butov, Kuzhko, Makeeva, and Butova, (2015). They found out that smoking
leads to mutation of the PM-T-330 gene IL-2 heterozygous type gene that produces white
blood cells which are part of the body’s natural response to microbial infection.
Besides smoking, compliance with drug susceptible TB treatment regimen was
also found to be associated with MRD-TB infection (p = 0.001). Chi-square test showed
that there is a high statistically significant difference (p = 0.001) found between Cases
and Control respondents that provided an answer relative to compliance with drug
susceptible TB treatment regimen. Despite the implementation of DOTS program by the
Philippines Department of Health, per the treatment outcome of 2011 new smear positive
cohort the default rate is 4% (Philippines Department of Health -National TB Control
Program, 2014). In a study by Smith, Wolff & Nguyen (2013) and Georghiou et al.
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(2012); noncompliance to the required TB treatment regimen such as repeated and
inappropriate use of antibiotic is a major cause of Mtb chromosomal mutation, which
then acquires antibiotic resistance specifically to the first line of drug treatment against
TB. Chromosomal mutation through horizontal gene transfer alters the original genetic
code due to repeated and inappropriate use of antibiotic (Smith, Wolff, & Nguyen, 2013).
The use and misuse of antibiotic in which case not following the prescribe TB treatment
regimen accelerate the emergence of drug resistant organism strain (WHO, 2015b).
Microorganism resistance to antibiotic is a threat to public health. Daniela and Osmand
(2011), and Skrahina et. al., (2013) identified in their respective study that history of
previous anti-TB treatment is a risk factor for MDR-TB infection. In the Philippines
despite the best effort of the Philippine Department of Health to provide free health care
services to TB patients and the general population; difficulty in accessing the health care
facilities is one of the primary reasons for not following the prescribed treatment. Most of
the respondents live in remote areas that going to the town health centers is a big
financial and physical sacrifice. Some patients will have to walk miles or ride on a nonmotorize boat to reach the town health center. Among the reasons cited by the
respondents for not following the TB treatment regimen is the unavailability of the
medicine every time they went to health centers. This is confirmed in the report of the
Philippines Department of Health -National TB Control Program (2014) wherein
medicine procurement challenges are encountered among which are: non-availability of a
source for Streptomycin and medicine requested shelf life of 18 months is too short for
the manufacturer to provide to the National Tuberculosis Control Program. The reasons
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cited by the respondents for not following the TB treatment regimen are: feeling better in
the middle of the treatment period, forgetfulness, and side effects of the medicine. The
stated reasons are not just confined to the Philippines. Economic barrier and easy access
to health which is affected by social and political factors are some of the commonly given
reasons why TB globally are still either not diagnosed, or their cases are not reported and
can also have a negative impact on treatment adherence (WHO,2015a).
Limitations of the Study
Understanding MDR-TB infection risk factors is very critical in epidemic
prevention. The increase in the prevalence rate of MDR-TB infection is of great concern
among public health practitioners (Zignol et al., 2012). This study was able to established
that in as far as the geographical area in the Philippines where the study was conducted;
smoking is a risk factor for MDR-TB infection which is similar to the study conducted by
Skrahina et al., (2013) in Belarus and Pant et al., (2009) done in a DOTS-Plus clinic at
Bhim Hospital, Bhairahawa . In addition, this study also found out that non-compliance
to drug susceptible TB treatment regimen is likewise a risk factors to MDR-TB infection.
The finding is a kin to findings of the study conducted by Terlikbayeva et al., (2012) in
Kazakhstan and in China by Chen et al., (2013). Smith, Wolff & Nguyen (2013) and
Georghiou et al. (2012) in their respective study concluded that noncompliance to the
required TB treatment regimen such as repeated and inappropriate use of antibiotic is a
major cause of Mtb chromosomal mutation.
This research study was able to bring-in together the research constructs in order
to understand the possible risk factors of MDR-TB infection in the Philippines. Once the
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researcher completed this study there were several aspects that were manifested which
forms the limitations to this study and includes the following:
1.

The study population is not a representative of the population in the Philippines

with Drug Susceptible TB and MDR-TB infection; thus results cannot be extrapolated to
the general Philippine population. Participants of this study were from limited geographic
areas which are the town health centers located in Leyte, San Mateo Rizal and patients
from the PMDT section of San Lazaro Hospital. The limited geographic study area where
the study population was recruited poses a threat to the external validity which limits the
generalizability of the study results (Creswell, 2009; Babbie, 2007). Therefore, the risk
factors associated to MDR-TB infection that was identified in this study could not be
applied in some parts of the country.
2.

Limited time, and logistical challenges when working without supporting

resources

(Supplemental staff from within the PDOH). Supporting resource through

the use of PDOH staff from the different area of the country could have expanded the
geographic area of the study and allow more respondents to participate in the survey.
Confirmation of this research should plan for an expanded set of support resources to
enable a representative study to be conducted.
3.

The questionnaire was not piloted and evaluated within the target population.

Questionnaire pilot study followed by evaluation is very critical to discover the
discrepancy and is very important in the standardization of the study instrument
(Nachmias and Nachmias, 2008).
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4.

Not all the 172 respondents provided answer to all items in the questionnaire

which may have biased the statistical test results. Further, the number of MDR-TB and
Drug Susceptible TB respondents were not equal. An equal number of respondents could
present a more careful interpretation existing between the variable (Babbie, 2007).
5.

The data in the study was obtained through questionnaire that is written in Pilipino

which is the national language of the country. This may have limited the number of
respondents since even with free elementary education some potential study respondents
cannot read and understand Pilipino thus were not able to be part of the study.
Understanding the question is very important in survey research in order to provide
accurate retrospective data. The questionnaire could have been written in the
respondent’s dialect so that it is easier and friendlier to the respondents, and could
provide a more accurate answer.
6.

Multivariate regression analysis could was not performed because of the limited

sample size in the study.

Recommendations
The primordial reason why the study was approve by the Philippine Department
of Health specifically the National Tuberculosis Control Program was that the topic was
in the research agenda of the TB program. Though the conclusion of the study cannot be
generally applied in the country because of the limited number of respondents and
geographical area covered, however the results of the study can provide baseline
information in case a similar nationwide study is conducted by the Philippine Department
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of Health. Based on the result of the data analysis gathered from this study, the following
are the suggested refinements in order to increase enrollment to the study which will
minimize unanswered questions and prevent the increase of MDR-TB infection in the
country.
1. Standardize the questionnaire so that the measuring instrument is most appropriate and
therefore measures what the study intend to know. In the original proposal, this was
part of Phase 1, however, due to the interest of time and geographical location of the
study area this was not pursued.
2. The questionnaire should be written in various dialects spoken by the respondents in
the area.
3. Obtain assistance from the staff of the health clinic to accommodate large number
respondents. Though it has to be noted that the original proposal called for this, but
the IRB insisted that the investigator not to utilize support staff in data collection.
4. Data should be collected following a face-to-face interview using the structured
questionnaire instead of traditional paper and pencil self-administration.
5. Request assistance from the PDOH staff to facilitate medical record reviews, help
with data collection/survey administration/data computerization) to enable inclusion
of a much larger representative sample of Pilipino with TB/MDR-TB cases from
around the Philippines.
6. Execute a pilot study to evaluate and assess that the aforementioned suggested
refinements have improved the response rate, the completion rate, and reduced
significantly the amount of missing information (unanswered questions).

103
7. HIV testing to TB patient in the Philippines is required among patient above 15 years
old, living in pre-identified priority areas and belong to high risk group (Philippines
Department of Health-National TB Control Program, 2014). The aforementioned
PDOH policy is not aligned with the WHO guidelines regarding routine HIV testing
of all persons diagnosed with TB, and testing all HIV-infected persons for evidence
of Mtb infection. I recommend revising current PDOH policy on HIV testing to
completely follow the WHO recommendation to prevent premature death of HIV
infected person from dying of TB, and avert the dissemination of TB (especially
MDR-TB) in the process.
8. It was found out in this study that one of the reasons cited by the respondents for not
following the TB treatment regimen is the unavailability of the medicine every time
they went to health centers. This is confirmed in the report of the Philippines
Department of Health -National TB Control Program (2014) wherein medicine
procurement challenges are encountered. The researcher propose that there should be
a regular supply of anti TB medicine to various towns’ health centers to make certain
that DOTS is strictly implemented.
9. Evaluate current system of anti TB medicine delivery to health centers to ensure
sustainable supply and ultimately improve patient compliance to treatment.
Implication for Social Change
Tuberculosis is the leading cause of morbidity and mortality in the Philippines
Vianzon, Garfin, Lagos, and Belena (2013). On the global scale, the country is the ninth
out of the 22 highest TB-burden countries and has one of the highest burdens of MDR-

104
TB (WHO, 2014a). The emergence of MDR-TB poses a serious threat to TB control in
developing countries; besides being difficult and expensive to treat, the disease requires a
longer period of treatment. WHO interactive database on the treatment outcomes of
MDR-TB cases in the Philippines showed that only 42% of the reported MDR-TB cases
in 2010 were successfully treated, 14% died, 2% failed treatment, 36% were lost to
follow-up, and 7% were not evaluated (WHO, 2014a).
There is no study in the Philippines on the risk factors of MDR-TB. The
Philippine Department of Health through the National Tuberculosis Control Program
agreed to approve the conduct of the study since the topic is on the research agenda of the
TB program. This study can help inform the planning of future nationwide MDR-TB
research through the lessons learned as discuss in the recommendation section of this
chapter.
The findings could contribute to positive social change in that they will provide
information to individual, TB Control program Director, and health care providers that
could help develop programs for drug susceptible TB to stop smoking and comply with
the anti TB drug treatment regimen to prevent MDR-TB infection. Further, the result of
the study can promote positive social change in that knowing the risk factor can provide
guidance to health workers in the identification of high-risk patients for MDR-TB
infection. The recognition of potential MDR-TB infected patient may help improve TB
case findings considering that the patient could potentially infect immediate members of
the family or person that he/she was in contact and which may result in increase of the
current national TB smear-positivity rate. Understanding the risk factors related to the
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onset of a disease is very critical in epidemic prevention. The persistent increase in the
prevalence rate of TB specifically MDR-TB (Zignol et al., 2012) continued to raise
concern among public health practitioners. The result of the study can guide in the early
identification of MDR-TB infection and treatment which will minimize the detrimental
biological, psychological and social effects of the disease.
Another positive social change in the study was that the researcher was able to interact
various TB Health Care Providers especially the personnel in the National Tuberculosis
Control Program of the Department of Health, Member of the Ethics Committee of San
Lazaro Hospital, PMDT Center of San Lazaro Hospital and Staff of the different Towns
Health Care Centers. The study provided an opportunity for the researcher to interact
with the different TB patients who were very candid and friendly in sharing their
thoughts about their current health conditions.
Conclusion
The primary goal of public health practitioner is to prevent the proliferation of
MDR-TB in the community. One method that is employed is through case finding using
risk factor. As such appreciating, the risk factors related to human infection of MDR-TB
is critical in case finding. Understanding the potential risk factor associated to MDR-TB
was consistent with the epidemiological theory of John Snow that was applied in this
study. He theorized that the cause of communicable disease can be determined using a
case-control study design to assess associations between potential risk factors
(independent variables) and the outcome (MDR-TB, the dependent variable) (Frerichs,
2009).
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Multidrug-resistant Mycobacterium tuberculosis accounts for 4.0% of all new
cases of TB in the Philippines (WHO, 2013a). Despite such high percentage rate of
MDR-TB infection in the Philippines, there is no study done that determine the possible
risk factors that contribute to the continued increase of MDR-TB infection in the country.
It is for this reason that the Philippine Department of Health through the National
Tuberculosis Control Program approved that the study be conducted for the subject of the
study is part of the NTP research agenda as well.
This research investigated the possible risk factors that are associated with MDRTB infection. The risk factors that were considered are: (a) previous TB treatment, (b)
infection with Human Immunodeficiency Virus, (c) exposure to TB patient, (d) delayed
TB diagnosis and treatment, (e) smoking, (f) imprisonment, (g) compliance with the TB
treatment regimen,( h) alcohol abuse, and (i)employment status.
Results were used to answer the research questions which established that drug
susceptible TB who smoke on a daily basis are three times likely to develop MDRT TB
infection. Further, data in this study indicated that drug susceptible TB patient is nine
times more likely to develop a MDR-TB infection if the anti TB treatment regimen is not
complied.
There are some limitations to this study that need to be taken into consideration
and that could contribute further to literature. Among the limitations was the
geographical location of the study area which limits the generalizability of the study
results. Another important limitation was to standardize the questionnaire, translate the
questions into various dialects, administer through face to face interview by the staff of
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the health clinic to accommodate large number respondents and minimize unanswered
questions.
The results of this study can add to the literature on MDR-TB infection in the
Philippines and as a bench mark for further studies that will be conducted by NTP on
the national level. The MDR-TB infection is a preventable disease. Education, health
guidance and counselling coupled with effective treatments through strict adherence to
DOTS are the keys to decreasing its prevalence.
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Appendix A: Request to Conduct Research

Name of the Clinic/Hospital Administrator
Address of the Clinic/Hospital

Dear Sir/Madam

This letter serves to request for your permission to conduct survey research on drug
susceptible TB and MDR-TB patients in your clinic/hospital/organization. I am presently
a Ph.D.in Public Health student at Walden University in the United States of America.
The title of my study is: “Possible Risk Factors of Multi-Drug Resistant Tuberculosis
Infection Prevention in the Philippines”. The proposed study will assess the strength of
association between several possible risk factors and the MDR-TB infection. The
research is done to fulfill the dissertation research requirement of the degree.
Once permission is granted by your good office the following procedure will be followed.
1. The researcher will provide to prospective study recruits the Study Information
and Participation Consent (in Filipino Language) and orientation discussion
where they are free to ask questions about the study and will be given ample time
around an hour to decide.
2. Once potential recruits volunteer consented in the study the researcher will assign
a study ID Number which will be entered in the data base, questionnaire and
respondent’s - clinical record extraction form.
3. The questionnaire that is in Filipino language will be placed inside an envelope
and distributed to respondents. The respondents will answer the questionnaire in
an area designated by your facility.
4. The respondents will hand over the envelope with the answered questionnaire to
the researcher for review and storage.
5.

The researcher will provide a list of patient to the clinic/hospital and the envelope
with the respondents clinical record extraction form.

6. Clinic/Hospital will be requested to review the patient clinical record to verify
whether the patient is either a laboratory confirmed MDR-TB or a laboratory
confirmed Drug Susceptible TB, and the most recent HIV test result (if available)
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and will be documented in the RESPONDENT’S - CLINICAL RECORD
EXTRACTION FORM.
7. The researcher will develop a data base for analysis to answer the research
questions.
Findings of the study can be shared to interested parties such as supporting study
participants, the supporting TB Centers, the Philippines DOH, and WHO.
No clinical test will be administered to patients who volunteered to be in the study, nor
will they be paid or receive any gifts for the participation in the study. It is hoped that the
research findings may help prevent others from developing MDR-TB.
The researcher’s Dissertation Committee and Walden University’s Institutional Review
Board (IRB) (identified below) will assure that ethical principles are adhered to
throughout the conduct of this research.
Donald Goodwin, DrPH,
Dissertation Committee Chair
Email [redacted]
IRB@waldenu.edu
Walden University
Research Participant Advocate
I hope that my request shall meet your favorable consideration
Yours Faithfully
Molovon P. Azores Jr.
Investigator
Student Ph.D. Public Health
College of Health Sciences
Walden University
E-mail: [redacted
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Appendix B: Respondents Clinical Record Extraction Form

Treatment Center: _______________________
Respondent’s Study ID No. _____________________

A.

Drug Susceptibility Testing (DST) Result
_____ No Resistance/Sensitive to Antibiotic
_____ Resistance to Antibiotic

M. tuberculosis/culture has been found resistance to:

_______ Isoniazid (INH)
_______ Rifampicin (RIF)
_______ Ethambutol (EMB) _______ Pyrazinamide (PZA)
_____________ Others

B.

Type of AIDS Test performed (if available): _____________

C.

HIV test result:
_________Positive _____ Negative
Date Tested: ___________

Documented by: ____________________

Date: __________
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Appendix C: Questionnaire
Respondent’s Study ID No. ________________
MDR-TB: _______

Non-MDR TB: ______

DEMOGRAPHIC INFORMATION
Instruction: Please check the appropriate answer.
1. Gender:
Male ___ Female: ___ No Answer: _______
2. Age: _____
3. Place of Birth: ____ Luzon _____ Visayas _____ Mindanao
4. What is your highest level of education?
None: _____ Elementary: _____ High school: _____
College: _____ Master’s: ______ Doctorate: ______
5. What is your employment status?
Unemployed: _____ Employed: ______
Retired: _____
6. What is your main source of income?
Fishing/Farming ______ Employment income ______
Business enterprise ______ Property Rental _______
Others, please specify _______
RISK FACTORS INFORMATION
A. Previous exposure to drug susceptible TB/MDR-TB patient, delayed
diagnosis and treatment
1. Do you know if you had been in contact or exposed to someone with TB before
you got the disease?
Yes ___
No __
Don’t Know ___
2. If “No” or “Don’t Know” please skip to Q5.
If yes where?
Home ____ Work-place ____
Friends ____ Prison
____ Others please specify_______________
3. How often were you in contact with someone with TB?
______ Occasionally _____ Monthly ___less than Monthly
4. How long had you been in contact with someone with TB before you were
diagnosed with TB?
Less than 2 months ______
2 to 6 months _____
More than 6 months ____
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5. Please check the symptoms that you had been experiencing before you were
diagnosed as having TB.
____ Cough that lasted 3 weeks or longer
____ Pain in the chest
____ Coughing up blood or sputum
____Weakness
____ Fatigue
____ Weight loss
____ No appetite
____ Chills
____ Fever
_____Sweating at night
____ Shortness of breath
6. Did you immediately visit a doctor or seek medical help?
Yes ____
No _______
If “No”, skip to Q8.
7. If yes, How long did it take to visit a doctor?
One week or less _____
Two weeks _____ 3 Weeks _____
A month _______
Greater than 1 month_______
I don’t remember ______
8. If you did not seek medical help immediately, why?
Please state: ______________________________
B. Previous TB treatment and compliance with treatment regimen
9. Is this your first time to have TB?
Yes _____
No _______
If “Yes”, skip to Section D.
10. Have you previously received TB treatment?
No ____
Yes ______
If “No”, skip to Section C.
11. Do you remember the drug prescribed to you?
Yes ____
No ____
If “No”, skip to Q13.
12. If yes please, please check the drug prescribed to you by the Doctor.
_______ Isoniazid (INH)
_______ Rifampicin (RIF)
_______ Ethambutol (EMB)
_______ Pyrazinamide (PZA)
_________________________ Others
13. Was your treatment supervised by Directly Observed Treatment Short (DOTS)
course personnel?
Yes ______
No _______
14. Did you follow the prescribed treatment regimen?
Yes _____
No _____
15. Why did you not follow the prescribed treatment regimen? Please specify
______________________________________________________________
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16. Did you complete the treatment?
Yes _____
No ______
If no, why did you stop the treatment? Please specify
__________________________________________________________

C. Human Immunodeficiency Virus
18. Have you been tested for HIV infection?
Yes ____
No ____
19. Have you been told by your doctor that you have HIV?
Yes _____
No ___
20. What month and year were you diagnosed to have HIV _________
21. Were you treated with HIV? ______ Yes

No_______

22. If so please check the medicine you took for HIV.
Agenerase (amprenavir)
Combivir (AZT + 3TC)
Complera (Truvada +
Crixivan (indinavir)
Edurant)
Edurant (rilpivirine)
Emtriva (emtricitabine)
Epivir (lamivudine, "3TC")
Fortovase (saquinavir)
Hivid (zalcitabine,
Fuzeon (enfuvirtide)
"ddC")
Invirase (saquinavir)
Kaletra (lopinavir)
Lexiva (fosamprenavir)
Norvir (ritonavir)
Retrovir (zidovudine,
Rescriptor (delavirdine)
"AZT")
Stribild (Emtriva +
Reyataz (atazanavir)
Viread + elvitegravir)
Sustiva (efavirenz
Tivicay (dolutegravir)
Triumeg (dolutegravir +
Trizivir
abacavir + lamivudine)
(AZT/3TC/abacavir)
Truvada (Emtriva + Viread)
Tybost (cobicistat)
Videx (didanosine, "ddI")
Viracept (nelfinavir)
Viramune (nevirapine)
Viread (tenofovir)
Vitekta (elvitegravir)
Zerit (stavudine, "d4T")
others
Ziagen (abacavir)
(please
specify)
D. Imprisonment
23. Have you been in prison?
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Yes _____
24. If yes, what year you went out of prison? _____

No _____

E. Smoking
25. Have you ever smoked cigarettes?
Yes ____
No _____
26. At what age did you start smoking cigarettes? ___________
27. Do you still smoke cigarettes at present?
Yes _____
No _____
28. Do you smoke cigarettes daily or occasionally?
Daily ______ Occasionally ____
29. How many cigarettes do you consume?
Less than 1 pack a week ________
1 pack a week ______
2 to 3 pack a week ______
More than 3 pack a week ______
Don’t know occasional only _____
30. Did you stop smoking? ________
31. At what age did you stop smoking? _______
F. Alcohol Consumption
32. Do you drink alcohol?
Yes ____ No _____
33. What type of alcoholic drink do you usually take?
Beer ______ Wine _____ Liquor/Spirit _____
Locally made alcohol drink (i.e. tuba, lambanog) ______
34. How often did you drink beer, wine, liquor/spirit or any locally made alcoholic
drink (i.e. tuba, lambanog)?
Every day ____

Once a week _____ Occasional only ______
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Appendix D: Translation Validation Form for Study Information and Consent Form
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Appendix E: Study Questionnaire Translated into Tagalog
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Appendix F: Permission to Conduct the Study from the Philippines Department of Health
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Appendix G: Approval to Conduct the Study from Burauen, Leyte Health Center
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Appendix H: Approval to Conduct the Study from Tanauan, Leyte Health Center
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Appendix I: Approval to Conduct the Study from Capoocan, Leyte Health Center
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Appendix J; Approval to Conduct the Study from Barugo, Leyte Health Center

142
Appendix K; Approval to Conduct the Study from Dagami, Leyte Health Center
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Appendix L; Approval to Conduct the Study from Carigara, Leyte Health Center
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Appendix M; Approval to Conduct the Study from San Mateo, Rizal Health Center
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Appendix N: Approval to Conduct the Study from San Lazaro Hospital

